Prevalence of overweight and obesity in people with severe mental illness: systematic review and meta-analysis

Medhia Afzal1,2, Najma Siddiqi1,2, Bilal Ahmad3,Nida Afsheen3, Faiza Aslam3, Ayaz Ali3, Rubab Ayesha3, Maria Bryant1,2, Richard Holt4,5, Humaira Khalid3, Kousar Ishaq3, Kamrun Nahar Koly6, Sukanya Rajan7, Jobaida Saba6, Nilesh Tirbhowan2, Gerardo A Zavala\*1

**Affiliations**

1 Department of Health Sciences, University of York, UK

2 Hull York Medical School, UK

3 Institute of Psychiatry, Rawalpindi Medical University, Pakistan

4 Human Development and Health, Faculty of Medicine, University of Southampton, UK

5 Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK

6 International Centre for Diarrhoeal Disease Research, Bangladesh

7 Department of Psychiatry, National Institute of Mental Health and Neurosciences, Banglore, India

**Corresponding author:** [**g.zavala@york.ac.uk**](mailto:g.zavala@york.ac.uk)

**Number of words:** 4315

**Number of tables:** 3

**Number of figures:** 6

**This manuscript was written using British spelling**

# 

# 

# 

# 

# Abstract

**Aims:** 1) To determine the pooled prevalence of overweight and obesity in people with severe mental illness (SMI), overall and by type of SMI, geographical region, and year of data collection; and 2) to assess the likelihood of overweight and obesity, in people with SMI compared with the general population.

**Methods:** PubMed, Medline, EMBASE, and PsycINFO databases were searched to identify observational studies assessing the prevalence of obesity in adults with SMI. Screening, data extraction and risk of bias assessments were performed independently by two co-authors. Random effect estimates for the pooled prevalence of overweight and obesity and the pooled odds of obesity in people with SMI compared with the general population were calculated. Subgroup analyses were conducted for types of SMI, setting, antipsychotic medication, region of the world, country income classification, date of data collection and sex. We assessed publication bias and performed a series of sensitivity analyses, excluding studies with high risk of bias, with low sample size and those not reporting obesity according to WHO classification.

**Result:** 120 studies from 43 countries were included, the majority were from high income countries. The pooled prevalence of obesity in people with SMI was 25.9% (95% C.I.=23.3-29.1) and the combined pooled prevalence of overweight and obesity was 60.1% (95% C.I. = 55.8-63.1). Sub-Saharan Africa (13.0%, 95%C.I.= 6.7-25.1) and South Asia (17.7%, 95%C.I.=10.5-28.5) had the lowest prevalence of obesity whilst North Africa and the Middle East (35.8%, 95%C.I.=23.8-44.8) reported the highest prevalence. People with SMI were 3.04 more likely (95% C.I.=2.42-3.82) to have obesity than the general population, but there was no difference in the prevalence of overweight. Women with schizophrenia were 1.44 (95% C.I.=1.25-1.67) times more likely than men with schizophrenia to live with obesity; however, no gender differences were found among those with bipolar disorder.

**Conclusion:** People with SMI have a markedly high prevalence and higher odds of obesity than the general population. This may contribute to the very high prevalence of physical health conditions and mortality in this group. People with SMI around the world would likely benefit from interventions to reduce and prevent obesity.

**Key words:** Severe mental illness; schizophrenia; bipolar disorder; obesity; overweight

# Contribution to the Field Statement

The prevalence of obesity in people with severe mental illness (SMI) has been estimated to be between 10 to 60% by a large number of studies from around the world; however, to date no synthesis of these studies exists. In the current review, we summarise the prevalence and trends for obesity from 120 studies across 43 countries, overall, and by type of SMI (e.g. schizophrenia and bipolar disorder), setting, region of the world, country income classification, sex and year of data collection. We report a pooled prevalence of obesity of just over 30%; people with SMI are three times more likely to have obesity compared with the general population. There were differences in the prevalence of obesity according to the geographical region, country income classification and sex. There was a disproportionately low number of studies from low- to middle- income countries (LMICs), particularly from Africa, the Middle East and Latin America regions. This is the first study to systematically estimate the pooled prevalence and patterns of obesity in people with SMI, and to report regional differences in this population.

# 

# Introduction

Obesity is a major global public health challenge [(1)](https://paperpile.com/c/oQGKXB/3G4o). The prevalence has steadily risen over recent decades, with rates tripling since 1975 to the point where 30% of the world’s population has either overweight or living with obesity [(1)](https://paperpile.com/c/oQGKXB/3G4o). According to the World Health Organization (WHO), the body mass index (BMI) provides the most useful, albeit crude, measure of population-level obesity [(2)](https://paperpile.com/c/oQGKXB/yzVT). People with severe mental illness (SMI), (defined as those with schizophrenia and psychotic disorders, bipolar disorder and major depressive disorder with psychotic features), have been reported to be disproportionately affected by the obesity epidemic [(3,4)](https://paperpile.com/c/oQGKXB/GN1J+ipFX). Studies from different countries and settings (inpatient, outpatient and community) around the world have reported prevalence of obesity ranging from 10% to 60%, suggesting the risk and prevalence of obesity in this population might vary by setting, country and region of the world [(5,6)](https://paperpile.com/c/oQGKXB/NQyv+2Ehe). Current data suggest that the prevalence of obesity among people with SMI is increasing at a faster rate than the general population [(7)](https://paperpile.com/c/oQGKXB/YUhd). The high prevalence of obesity has been attributed to a combination of side effects and increased appetite associated with psychotropic medication, clustering of health risk behaviours such as poor diet with a high content of saturated fats [(8)](https://paperpile.com/c/oQGKXB/Ewu8), low engagement with physical activity [(9)](https://paperpile.com/c/oQGKXB/b5Zj), and social determinants of poor health such as stigma and poverty [(10)](https://paperpile.com/c/oQGKXB/NWpOv).

Obesity leads to metabolic disorders such as diabetes and cardiovascular disease, musculoskeletal disorders, cancers and premature death. People with SMI have nearly twice the risk of dying from cardiovascular disease and die on average 10 to 20 years earlier than the general population [(11)](https://paperpile.com/c/oQGKXB/nzMy). Concerningly, this mortality gap appears to have widened in recent decades [(12,13)](https://paperpile.com/c/oQGKXB/pJSC+jEbV9). It is estimated that 33% of the excess mortality in SMI is attributable to obesity and its comorbidities [(14-16)](https://paperpile.com/c/oQGKXB/MHFK+hsVA).

Currently there are no systematic reviews reporting the prevalence and trends of obesity in people with SMI. Previous reviews have focused predominantly on the metabolic syndrome in this population [(11,12,17)](https://paperpile.com/c/oQGKXB/xaD5+pJSC+nzMy). One review included data for all types of SMI and two reviews focused solely on people with schizophrenia. In all these studies, only abdominal obesity based on waist circumference was reported as a component of metabolic syndrome or as a secondary outcome, which means that studies that measured obesity using body mass index (BMI) may have been missed. This is an important gap as overweight and obesity are found to be earlier on the causal pathway that leads to metabolic syndrome, and thus deserve to be explored independently (9). Moreover, separately from the metabolic pathway, they are associated with additional adverse outcomes (e.g. osteoarthritis, mental disorders and sleep apnoea).

An up-to-date synthesis examining the prevalence of overweight and obesity is needed to raise awareness amongst stakeholders and policymakers about the extent of the obesity epidemic in people with SMI. This can inform strategies and interventions to address the problem and help reduce health inequalities for this population. The aims of this study were: 1) to determine the overall pooled prevalence of overweight and obesity and prevalence by type of SMI, setting, geographical region, country economy classification, year of data collection and sex; and 2) to assess the likelihood of obesity in people with SMI compared with matched controls from the general population.

# Materials and Methods

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)[(18)](https://paperpile.com/c/oQGKXB/VfUU) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines [(19)](https://paperpile.com/c/oQGKXB/qUSb). The protocol has been registered and published in the International prospective register of systematic reviews (PROSPERO) [CRD-42020200380](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020200380) [(20)](https://paperpile.com/c/oQGKXB/VnmJ).

## Search strategy

We conducted a systematic search of PubMed, Medline, EMBASE, and PsycINFO databases with the help of an information specialist. Studies published from the date of inception up to July 2020 were included. Combining the following key words, the search terms used were: 1) Population (*“severe mental illness” OR “serious mental illness” OR “schizophrenia” OR “psychosis” OR “psychotic” OR “psychotic disorder\*” OR “psychosis” OR “schizoaffective” OR “schizo-affective” OR “bipolar disorder\*” OR “mania” OR “manic” OR “bipolar” OR “depression” OR “major depressive disorder” or “antipsychotic” )*; 2) Outcome***(****BMI OR “Body Mass Index” OR weight OR “waist circumference” OR “waist to hip ratio” OR “percentage body fat” OR obesity OR overweight OR underweight OR thinness OR undernourished\* OR malnutrition \* OR* undernutrition \* OR adiposity); 3) study design **(***epidemiology\* OR prevalence OR cross-sectional OR “ cohort” OR longitudinal OR observant OR observational OR case-control OR survey).* In addition, we conducted citation searches for included studies and relevant systematic reviews to identify any relevant additional studies.

## Study selection

### For the systematic review and the meta-analysis we included studies according to the following criteria:

### 1) Studies including adult populations (aged ≥18 years) with a diagnosis of a SMI (schizophrenia spectrum disorders, bipolar affective disorder and major depression with psychosis), using definitions of any standardised tool such as the International Classification of Diseases (ICD)[(3)](https://paperpile.com/c/oQGKXB/GN1J), or the Diagnostic and Statistical Manual of Mental Disorders (DSM)[(21)](https://paperpile.com/c/oQGKXB/CNVh);

### 2) Studies reporting the prevalence of obesity using body mass index (BMI) using any established standardised definition, such as the WHO [(22,23)](https://paperpile.com/c/oQGKXB/DYvV+7NLZ);

### 3) Observational studies (e.g., cross-sectional, prospective or retrospective cohort studies, and case-control or studies).

### Qualitative studies, studies with a sample size below 30, case reports, and studies where the majority of the population were under 18 years of age were excluded. We originally intended to include papers in any language, however due to time and resource restrictions, we excluded papers in a language other than English.

## Outcomes

Primary: prevalence of obesity among people with SMI. Secondary: Prevalence of overweight and combined prevalence of overweight and obesity among people with SMI; and prevalence of overweight, obesity and combined prevalence of overweight and obesity in matched controls from the general population (when available). Overweight (25-29.9 Kg/m2) and obesity (≥30 Kg/m2) were defined according to the WHO BMI cut-off points for most populations[(22)](https://paperpile.com/c/oQGKXB/DYvV). However, we also included studies presenting ethnicity adjusted classifications which usually have a lower cutoff score for overweight (23–27.4 kg/m2) and obesity (≥27.5 Kg/m2)[(23)](https://paperpile.com/c/oQGKXB/7NLZ).

## Data Extraction (selection and coding)

Data screening and selection were completed using Covidence (Melbourne, Australia)[(24)](https://paperpile.com/c/oQGKXB/SJ2l). Two of four independent co-authors (AA, HK, MA, NT) completed screening of records (titles and abstracts); disagreements were resolved by consensus or in consultation with a third independent author (KK, GZ). Full texts were retrieved for those records considered eligible and for those where there was insufficient information from the abstract. For each included study data were extracted and reviewed by two of four independent authors using a pre-designed data extraction form (BA, JS, KK, RA). The extracted information included: title, authors, year of data collection, study design, study setting (inpatient, outpatient, and community-based), sample size, geographical region based in the World Bank region classification[(25)](https://paperpile.com/c/oQGKXB/X4kP), World Bank country income classification (Low and middle income countries (LMIC) or High income countries (HIC))[(25)](https://paperpile.com/c/oQGKXB/X4kP), antipsychotic medication use (antipsychotic-naive cohort versus antipsychotic exposed and mixed SMI population), SMI diagnosis criteria, BMI classification criteria and prevalence estimates of overweight and obesity. When available in the studies we also extracted the prevalence of overweight and obesity by sex and for matched controls from the general population independently. Where there was more than one paper for the same study we selected the paper with the largest sample size or most recent date of publication (if the sample size was the same). In papers where the estimates of obesity were reported independently by country or type of SMI, they were separated and considered as independent studies.

## Risk of bias

The quality of included studies was evaluated by two independent co-authors (KI, SR) according to criteria from the Joanna Briggs Institute (*JBI) Critical Appraisal Checklist* [*(26)*](https://paperpile.com/c/oQGKXB/FfPV)**.** An overall risk of bias assessment was conducted for each study following the procedure suggested by the Cochrane RoB tool [(27)](https://paperpile.com/c/oQGKXB/dmjh). If all domains of the tool were scored as “yes” or only one of the domains was assessed as “unclear” the study was classified as “low risk of bias”; if two or three domains were assessed as “unclear” the study was classified as “medium risk of bias”; and if four or more were assessed as “unclear” or at least one was assessed as “no” the study was classified as “high risk of bias”[(28)](https://paperpile.com/c/oQGKXB/aAX7).

## Data analysis

### Descriptive analysis

Data from eligible studies were summarised providing information on the number and frequency of studies according to the World Bank income classification, the World Bank geographical region, type of SMI (schizophrenia, bipolar disorders, or a combination of SMI operationalized as “any”), the diagnostic tool to define the SMI, the study design, year of data collection, BMI classification, sex and overall risk of bias. Using standard procedures, we imputed the year of data collection, whenever this information was not available [(29)](https://paperpile.com/c/oQGKXB/upelj).

### Meta-analysis

We conducted three separate meta-analyses using random effect models to account for the high heterogeneity expected between the studies. The first determined the pooled prevalence of overweight, prevalence of obesity and combined prevalence of overweight and obesity. The second calculated the odds of overweight or obesity in people with SMI compared with the general population. The third estimated the odds of women with SMI having overweight and obesity compared to men with SMI. For the second and third meta-analysis, we used only the studies with available data on overweight and obesity for matched controls from the general population or men and women independently. Results are presented as odds ratios with 95% CI. We generated forest plots calculating the pooled prevalence and pooled odds ratios according to the type of SMI, setting, medication use, World Bank region, World Bank country income classification, and date of data collection.

Heterogeneity of studies was determined by inspecting forest plots and using the chi-square test for heterogeneity with a 10% level of statistical significance, and the I2 statistic. All analyses were performed using the metafor package in R V4.1.1 (Vienna, Austria)[(30)](https://paperpile.com/c/oQGKXB/5aqR). We assessed publication bias by a visual inspection of a funnel plot of the log transformed proportion versus the standard error.

### Sensitivity analyses

To evaluate the robustness of the results we performed a series of sensitivity analyses. In the first analysis, we removed the studies assessed as “high risk of bias”. In the second, we removed studies that had an obesity cut-off point that differed from the WHO classification. In the third, we excluded studies with a sample size smaller than 323 (because this is the sample size needed to estimate the prevalence of obesity with a precision of 0.05 and confidence of 0.95, assuming a prevalence of 30%). We conducted the same set of analyses and compared the pooled estimate of obesity and heterogeneity with the data which included all studies [(31)](https://paperpile.com/c/oQGKXB/hwVc).

### 

We mapped the pooled prevalence of obesity by country in a world map. For countries with more than one study we calculated a weighted mean using data from all available studies. The maps were generated using the Rworldmap library in R V4.1.1 (Vienna, Austria)[(30)](https://paperpile.com/c/oQGKXB/5aqR).

# Results

As shown in the PRISMA chart (Figure 1) we screened 12,653 reports, identified 725 that fulfilled the inclusion criteria (one could not be retrieved [(32)](https://paperpile.com/c/oQGKXB/5p82)), and extracted data from 107 reports. Eight reports had duplicated data from the same cohort of people with SMI, we only kept the four reports with the most recent date of publication. We separated the prevalence of obesity for each country from a report that provided obesity estimates in 10 European countries and one from six Asian countries. We also separated the prevalence of obesity for each SMI condition in three reports that provided estimates separately for people with schizophrenia and bipolar disorders. We extracted 120 estimates of obesity, 108 estimates of overweight, 24 estimates of the prevalence of obesity in the general population and 30 estimates of obesity for men and women separately. The complete list of the papers is provided in the supplementary material. We found less than 10% of disagreements in the title and abstract and full text screening and less than 5% in data extraction, indicating good interrater reliability.

**Figure 1.** PRISMA chart

Table 1 summarises characteristics of the 107 papers providing 120 estimates of obesity (called studies hereafter), including 139,282 people with SMI. The sample size of the studies ranged from 30 to 43,093 with a mean of 267. The sample ages ranged from 21.3 years to 70.4 years with a mean of 41.3 years. We found 95 studies (79.1%) from HICs and 25 (20.1%) from LMICs, including data from 43 countries; more than 50% of the studies were conducted in the regions of Europe and North America, whilst the percentage of studies from the regions of Sub-Saharan Africa (2.4%), South Asia (4.0%), Middle East and North Africa (1.6%), and Latin America and the Caribbean (4.8%) were low. More than 80% of the studies classified SMI according to DSM and ICD criteria and 90% of the studies used the WHO classification of overweight and obesity.

## Risk of bias

Fifty eight percent of the studies were classified as having “low” risk of bias, 22.5% as “medium” risk of bias and almost 20% were classified as having “high” risk of bias (Table 1 and supplementary material ).

## Prevalence of overweight and obesity in people with SMI

As shown in Figure 2 and Table 2, the pooled prevalence of obesity in this population was 25.9% (95% C.I. = 23.3-29.1) and the combined prevalence of overweight and obesity was 60.1% (95% C.I.=55.8-63.1). The pooled prevalence of obesity was 22.4% (95% C.I.=17.2-27.3) in LMICs and 27.1% (95% C.I.=24.1-29.9) in HICs, and the combined prevalence of overweight and obesity was 55.7% (95% C.I.=49.5-61.7) in LMICs and 60.7% (95% C.I.= 56.9-64.2) in HICs. The region with the lowest prevalence of obesity was Sub-Saharan Africa with a pooled prevalence of 13.3% (95% C.I.=6.7-25.1), followed by South Asia with a pooled prevalence of 17.7% (95% C.I. = 10.5-28.5). The regions with the highest prevalence of obesity were the Middle East and North Africa with obesity prevalence of 35.8% (95% C.I. = 23.8-44.8) and a combined overweight and obesity prevalence of 71.4% (95% C.I. = 67.8-74.7). There were no differences in the prevalence of obesity between studies performed in antipsychotic-naive populations (33.7% (95% C.I. =24.8-43.8)) and those in people prescribed antipsychotics (30.6% (95% C.I. = 29.4-32.1)). There were no substantial differences in the prevalence of overweight and obesity between the types of SMI and between inpatient, outpatient, or community settings. We found substantial heterogeneity ( I2 =88-98%, p<0.01) in overall estimates, which was not reduced in the subgroup estimates ( I2 =97-98%, p<0.01).

**Figure 2.** Prevalence of obesity in people with SMI according to type of SMI, region, World Bank classification and year of data collection

As shown in Figure 3, the countries with the highest prevalence of obesity (over 40%) were Germany, Italy and the UK. While the countries with the lowest reported prevalence were Ethiopia and Uganda. There were no available estimates in most of the countries in the regions of Africa, the Middle East and Latin America.

**Figure 3.** Geographical variation in the prevalence of obesity in people with SMI

Figure 4 shows trend lines of the prevalence of obesity in each geographical WorldBank region over time. There was a decreasing trend in the prevalence of obesity in the region of Europe and Central Asia; in contrast there was an increasing trend in the regions of Latin America and the Caribbean, Middle East and North Africa, North America, South Asia and Sub-Saharan Africa.

**Figure 4.** Weighted linear regression models between the prevalence of obesity and time according to World Bank region.

*Footnote figure 4. Data on global trends in the prevalence of obesity in people with SMI from 1995 to 2020 from the World Bank regions of the world show differences in the trend of the prevalence of obesity. The area of the dots corresponds to the sample size of each study. WB: World Bank; SMI: Severe mental illness.*

## Obesity in people with SMI compared with the general population

Twenty four studies reported the prevalence of obesity in the general population by using matched controls. As seen in Table 3, people with SMI were 3.04 (95% C.I. = 2.42 - 3.82) times more likely to have obesity and 2.03 (95% C.I. = 1.60 - 2.59) times more likely to have either overweight or obesity compared with the general population. People with SMI in the East Asia and Pacific region were 4.84 (95% C.I. = 2.80 - 7.00) times more likely to have obesity than people in the general population, while people with SMI from Europe and Central Asia had 2.21 (95% C.I. = 1.52 - 3.22) higher odds (figure 5). There were no differences in the odds of people with SMI being overweight compared with the general population. We found high heterogeneity between the studies both in the overall (88%) and subgroup estimates (88-93%).

**Figure 5.** Odds of people with SMI of having obesity as compared to the general population

**Sex differences in the prevalence of obesity in people with SMI**

As shown in figure 6, twenty four studies reported obesity outcomes independently for men and women; the meta-analysis from these studies showed that women with schizophrenia were 1.46 (95% C.I. = 1.23-1.72) times more likely to have obesity and 1.27 (95% C.I. = 1.16-1.39) more likely to be overweight compared with men with schizophrenia. There were no differences in the odds of obesity between men and women with bipolar disorder or any SMI.

**Figure 6.** Association between sex and obesity in people with SMI

## Sensitivity analysis and publication bias

The pooled prevalence of obesity did not change substantially (more than 1.2%) when studies with high risk of bias, BMI classification other than WHO, and small sample sizes were removed. The model excluding studies with high risk of bias (n= 95) had a pooled estimate of obesity of 25.6% (95% C.I. = 22.8-28.7%;I2=98.2, t2=0.57); the model excluding studies (n=109) with cut-off values different from the WHO gave a pooled prevalence of 25.3% (22.7 - 28.2%; I2=97.9, t2=0.56); and the model excluding studies with small sample sizes (n=43) showed a pooled prevalence of 27.1% (22.8=38.1%; I2=99.1, t2=0.58). As shown in the funnel plot (see supplementary material), there was no evidence of publication bias.

# Discussion

## Main findings

This review provides the first comprehensive overview of the prevalence of overweight and obesity among people with SMI, with data from 43 countries from all regions of the world. We found a high prevalence of overweight and obesity and higher odds of people with SMI living with obesity than the general population in all regions. There were differences in the prevalence of obesity according to the geographical region, country income classification and sex. We also found regional differences in the trend of obesity in this population. There was a disproportionately low number of studies from LMICs, particularly from Sub-Saharan Africa, the Middle East and Latin American regions.

## Prevalence of overweight and obesity

The high prevalence of overweight and obesity found in this SMI population and the higher odds of obesity compared with the general population is consistent with epidemiological data, where the prevalence of obesity in the general population was lower than the prevalence found in people with SMI across all regions of the world such as Africa (12.7%), Americas (27%), Europe (22.5%), and West Pacific and East asia (5.4%)[(33)](https://paperpile.com/c/oQGKXB/QrdJ). The high prevalence of obesity found in people with SMI is likely to be linked to the use of antipsychotic medications and unhealthy lifestyle behaviours which are more common in SMI[(34–36)](https://paperpile.com/c/oQGKXB/nnps+nL78+bP5w). Despite the high prevalence of obesity and the excess mortality, studies have consistently shown that this population has poorer access to health risk modification advice and lifestyle interventions to prevent and treat obesity compared with the general population[(37)](https://paperpile.com/c/oQGKXB/fRQn). These disparities are even greater in LMICs, where poverty affects a higher proportion of the SMI population and where access to healthcare is even more limited, and where evidence of availability and effectiveness of lifestyle intervention among people with SMI is nearly non-existent [(38,39)](https://paperpile.com/c/oQGKXB/MAkO+tiME). Implementation of screening programmes assessing overweight and obesity might be useful to identify people at higher risk, and referral to lifestyle interventions and collaborative care as suggested by the WHO guidelines for management of physical conditions in adults with SMI [(8)](https://paperpile.com/c/oQGKXB/Ewu8). Despite the multiple barriers faced by this population such as stigma, illness symptoms and low motivation, the few pharmacological and lifestyle interventions available to prevent and treat obesity in this population have proven to be effective to maintain and reduce body weight [(39–42)](https://paperpile.com/c/oQGKXB/2zJB+n7du+GFMm+tiME). In addition, they have shown benefits in other parameters such as fasting blood glucose, hypertension and dyslipidemia [(43)](https://paperpile.com/c/oQGKXB/7VEm). Thus, lifestyle and pharmacological interventions could provide a feasible and cost-effective solution to reduce obesity, prevent non-communicable diseases (NCDs) and contribute to reduction of the mortality gap seen in this population [(44)](https://paperpile.com/c/oQGKXB/O2TG).

The geographical differences in the prevalence and trends of obesity are also found in the general population [(33)](https://paperpile.com/c/oQGKXB/QrdJ), and may be associated with socio-economic inequalities, lifestyle, food availability and other environmental and genetic factors in each region [(45)](https://paperpile.com/c/oQGKXB/twcZ). These differences should be taken into consideration in developing tailored interventions and programmes to prevent and treat obesity in each country or region [(46)](https://paperpile.com/c/oQGKXB/8xs4). Special attention should be placed in countries and regions where the prevalence of obesity is high and where there is an increasing trend in the prevalence. An unexpected finding of the review was the higher prevalence of obesity (although not statistically significant) in studies conducted in an antipsychotic naive population compared with studies where the participants were on psychotropic medication. These findings should be interpreted with caution since the estimate of obesity for antipsychotic naive populations comes from only seven studies conducted in Europe and North America, which reported a high prevalence of obesity.

The sex differences concerning the burden of overweight and obesity are also seen in the general population [(47)](https://paperpile.com/c/oQGKXB/Katm), where the prevalence of overweight and obesity is higher among women especially in LMICs [(36,48)](https://paperpile.com/c/oQGKXB/nrD9+bP5w). Studies looking specifically into gender differences have found fewer gender differences in health outcomes in people with bipolar disorder [(49)](https://paperpile.com/c/oQGKXB/gjkx) than those with schizophrenia [(50,51)](https://paperpile.com/c/oQGKXB/3KWs+BZiE). It has been suggested that interventions to prevent and treat obesity should be tailored to the sex of the participant to increase their acceptability and effectiveness [(52)](https://paperpile.com/c/oQGKXB/hMUD).

## Disparities between HICS and LMICs

Even if we consider the papers other than English (supplementary material), we found a disproportionately low number of studies from LMICs and, in particular, a big gap in the evidence available from Sub-Saharan Africa and Latin American regions. These disparities in the contribution of LMICs in health research have been highlighted in other health disciplines [(53,54)](https://paperpile.com/c/oQGKXB/6V19+6J3G). Possible explanations could include challenges such as stigmatized health conditions, inadequate health care infrastructure, lack of national budget designated to the mental health sector and research budget [(55)](https://paperpile.com/c/oQGKXB/wM05). Collecting information on the prevalence of obesity and other physical conditions is needed in these regions to develop health policy and tailored programmes and interventions that might improve health and reduce inequalities in this population. Approaches such as the “Investigating Mental and Physical Health Together” (IMPACT) SMI survey could be used to collect and analyse data on obesity, NCDs and health risk behaviours in this population in a cost-effective manner in a budget restricted setting [(56)](https://paperpile.com/c/oQGKXB/JFAG).

## Strengths and limitations

There are some limitations that require acknowledgment. First, because of the diversity in the regions, type of SMI and setting, there was substantial heterogeneity between the studies, which could not be reduced by stratifying the sample. However, we did not find evidence of publication bias and performed sensitivity analyses that supported the robustness of our results. Second, there was not a consistent definition of obesity across studies conducted in Asia which may have led to the overestimation of the prevalence of obesity, to address this we conducted sensitivity analysis excluding these studies and providing the data of the prevalence of obesity using only these studies. Third, there were also minor deviations from the protocol, such as the inclusion of papers written in all languages , which was not possible due to resources and time constraints, this may have affected the estimates of obesity especially in China, Turkey and Russia (were most of these publications in other languages came from – A list of these publications are available in the supplementary material-) ; the use of any validated definition of obesity rather than only the WHO, which was changed to be more inclusive particularly studies conducted in Asia; we stated we would only conduct a meta-analysis if the heterogeneity between the studies was low, however after inspection of the data we decided to provide an estimate acknowledging this limitation. Fourth, we could not account for unmeasured confounders such as diet and physical activity that could have affected the prevalence of obesity in each study. Despite these limitations this is the first study to examine the prevalence of obesity and overweight in people with SMI from a global perspective estimating the prevalence and trend of obesity in every region of the world.

# Conclusion

People with SMI have a high prevalence of obesity and higher odds of having obesity than the general population. This may be contributing to the higher morbidity and mortality seen in this population. This study demonstrated regional and sex differences in the prevalence and trends of obesity. The progression from obesity to metabolic diseases and premature mortality in this population should be assessed in more detail. People with SMI around the world could benefit from screening programs and tailored interventions to reduce and prevent obesity.

# Conflict of interests

*The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest*.

# Author contributions

GZ, MA, NS and RH designed the study, GZ and MA drafted the manuscript, MB, NS and RH made substantial contributions to conception of the manuscript and interpretation of data, AA, BA, FA, HK, JS, KI, KK, NT, RA and SR made substantial contributions to screening and data extraction and BA, GZ and RA conducted the analysis, MB, NS, and RH critically revised the manuscript. All authors read and approved the final manuscript.

# Funding

This research was funded by the National Institute for Health Research (NIHR) (Grant: GHRG 17/63/130:) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care.

# References

1. [Organization WH, Others. Obesity and overweight.[Online]. 2020. URL: https://www who int/news-room/fact-sheets/detail/obesity-and-overweight. 27.](http://paperpile.com/b/oQGKXB/3G4o)

2. [World Health Organization. Obesity: Preventing and Managing the Global Epidemic. World Health Organization; 2000. 253 p.](http://paperpile.com/b/oQGKXB/yzVT)

3. [World Health Organization, WHO Staff, WHO. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization; 1992. 362 p.](http://paperpile.com/b/oQGKXB/GN1J)

4. [Scott D, Happell B. The high prevalence of poor physical health and unhealthy lifestyle behaviours in individuals with severe mental illness. Issues Ment Health Nurs. 2011;32(9):589–97.](http://paperpile.com/b/oQGKXB/ipFX)

5. [McCarron RM, Xiong GL, Keenan CR, Nasrallah HA. Preventive Medical Care in Psychiatry: A Practical Guide for Clinicians. American Psychiatric Pub; 2015. 482 p.](http://paperpile.com/b/oQGKXB/NQyv)

6. [Naslund JA, Aschbrenner KA, Scherer EA, Pratt SI, Wolfe RS, Bartels SJ. Lifestyle Intervention for People With Severe Obesity and Serious Mental Illness. Am J Prev Med. 2016 Feb;50(2):145–53.](http://paperpile.com/b/oQGKXB/2Ehe)

7. [Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med. 2009 Apr;36(4):341–50.](http://paperpile.com/b/oQGKXB/YUhd)

8. [Organization WH, Others. Management of physical health conditions in adults with severe mental disorders: WHO guidelines. 2018; Available from:](http://paperpile.com/b/oQGKXB/Ewu8) <https://apps.who.int/iris/bitstream/handle/10665/275718/9789241550383-eng.pdf>

9. [Osborn DPJ, Nazareth I, King MB. Physical activity, dietary habits and Coronary Heart Disease risk factor knowledge amongst people with severe mental illness: a cross sectional comparative study in primary care. Soc Psychiatry Psychiatr Epidemiol. 2007 Oct;42(10):787–93.](http://paperpile.com/b/oQGKXB/b5Zj)

10. [Mai Q, Holman CD, Sanfilippo FM, Emery JD. The impact of mental illness on potentially preventable hospitalisations: a population-based cohort study. BMC Psychiatry. 2011;11:163.](http://paperpile.com/b/oQGKXB/NWpOv)

11. [DE Hert M, Schreurs V, Vancampfort D, VAN Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009 Feb;8(1):15–22.](http://paperpile.com/b/oQGKXB/nzMy)

12. [Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015 Oct;14(3):339–47.](http://paperpile.com/b/oQGKXB/pJSC)

13. [Liu NH, Daumit GL, Dua T, Aquila R, Charlson F, Cuijpers P, et al. Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry. 2017 Feb;16(1):30–40.](http://paperpile.com/b/oQGKXB/jEbV9)

14. [Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009 Aug 22;374(9690):620–7.](http://paperpile.com/b/oQGKXB/MHFK)

15. [Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010 Feb;196(2):116–21.](http://paperpile.com/b/oQGKXB/hsVA)

16. [Schelbert KB. Comorbidities of obesity. Prim Care. 2009 Jun;36(2):271–85.](http://paperpile.com/b/oQGKXB/YCgY)

17. [Mitchell AJ, Vancampfort D, Sweers K. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophrenia [Internet]. 2013; Available from:](http://paperpile.com/b/oQGKXB/xaD5) <https://academic.oup.com/schizophreniabulletin/article-abstract/39/2/306/1823895>

18. [Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement [Internet]. Vol. 6, PLoS Medicine. 2009. p. e1000097. Available from:](http://paperpile.com/b/oQGKXB/VfUU) <http://dx.doi.org/10.1371/journal.pmed.1000097>

19. [Stroup DF, Berlin JA, Morton SC, Olkin I, David Williamson G, Rennie D, et al. Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting. JAMA. 2000 Apr 19;283(15):2008–12.](http://paperpile.com/b/oQGKXB/qUSb)

20. [Afzal M, Siddiqi N, Zavala G. Prevalence of obesity, overweight and underweight in people with severe mental illness: systematic review. International prospective register of systematic reviews [Internet]. 2020; Available from:](http://paperpile.com/b/oQGKXB/VnmJ) <https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020200380>

21. [Frances A, First M, Pincus HA, Widiger T, Davis W. An Introduction to DSM-IV [Internet]. Vol. 41, Psychiatric Services. 1990. p. 493–4. Available from:](http://paperpile.com/b/oQGKXB/CNVh) <http://dx.doi.org/10.1176/ps.41.5.493>

22. [Organization WH, Others. Overweight and obesity. 2020; Available from:](http://paperpile.com/b/oQGKXB/DYvV) <https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-asia-pacific-2020_a47d0cd2-en>

23. [WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004 Jan 10;363(9403):157–63.](http://paperpile.com/b/oQGKXB/7NLZ)

24. [Covidence. Covidence. 2016;](http://paperpile.com/b/oQGKXB/SJ2l)

25. [Fantom, Neil James, Serajuddin U. The World Bank’s Classification of Countries by Income [Internet]. 2016 [cited 2021 Aug 11]. Available from:](http://paperpile.com/b/oQGKXB/X4kP) <https://papers.ssrn.com/abstract=2741183>

26. [Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020 Oct;18(10):2127–33.](http://paperpile.com/b/oQGKXB/FfPV)

27. [Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons; 2019. 728 p.](http://paperpile.com/b/oQGKXB/dmjh)

28. [Lundh A, Gøtzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC Med Res Methodol. 2008 Apr 21;8:22.](http://paperpile.com/b/oQGKXB/aAX7)

29. [Spineli LM, Pandis N, Salanti G. Reporting and handling missing outcome data in mental health: a systematic review of Cochrane systematic reviews and meta-analyses. Res Synth Methods. 2015 Jun;6(2):175–87.](http://paperpile.com/b/oQGKXB/upelj)

30. [R Core Team. R: A language and environment for statistical ## computing. R Foundation for Statistical Computing, Vienna, Austria [Internet]. 2020. Available from:](http://paperpile.com/b/oQGKXB/5aqR) [https://www.R-project.org/](https://www.r-project.org/)

31. [Moutinho L. Sample Size for Proportions [Internet]. The SAGE Dictionary of Quantitative Management Research. p. 279–81. Available from:](http://paperpile.com/b/oQGKXB/hwVc) <http://dx.doi.org/10.4135/9781446251119.n83>

32. [Susce MT, Villanueva N, Diaz FJ, de Leon J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry. 2005 Feb;66(2):167–73.](http://paperpile.com/b/oQGKXB/5p82)

33. [Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019 Mar;92:6–10.](http://paperpile.com/b/oQGKXB/QrdJ)

34. [McCloughen A, Foster K. Weight gain associated with taking psychotropic medication: an integrative review. Int J Ment Health Nurs. 2011 Jun;20(3):202–22.](http://paperpile.com/b/oQGKXB/nnps)

35. [Álvarez-Jiménez M, González-Blanch C, Crespo-Facorro B, Hetrick S, Rodriguez-Sánchez JM, Pérez-Iglesias R, et al. Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders. CNS Drugs. 2008 Jul 1;22(7):547–62.](http://paperpile.com/b/oQGKXB/nL78)

36. [Bradshaw T, Mairs H. Obesity and Serious Mental Ill Health: A Critical Review of the Literature. Healthcare (Basel). 2014 Apr 1;2(2):166–82.](http://paperpile.com/b/oQGKXB/bP5w)

37. [Maj M. Physical health care in persons with severe mental illness: a public health and ethical priority. World Psychiatry. 2009 Feb;8(1):1–2.](http://paperpile.com/b/oQGKXB/fRQn)

38. [Naslund JA, Whiteman KL, McHugo GJ, Aschbrenner KA, Marsch LA, Bartels SJ. Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: A systematic review and meta-analysis. Gen Hosp Psychiatry. 2017 Jul;47:83–102.](http://paperpile.com/b/oQGKXB/MAkO)

39. [Verhaeghe N, De Maeseneer J, Maes L, Van Heeringen C, Annemans L. Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review. Int J Behav Nutr Phys Act. 2011 Apr 11;8:28.](http://paperpile.com/b/oQGKXB/tiME)

40. [Teasdale SB, Ward PB, Rosenbaum S, Samaras K, Stubbs B. Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness. Br J Psychiatry. 2017 Feb;210(2):110–8.](http://paperpile.com/b/oQGKXB/2zJB)

41. [Hiluy JC, Nazar BP, Gonçalves WS, Coutinho W, Appolinario JC. Effectiveness of Pharmacologic Interventions in the Management of Weight Gain in Patients With Severe Mental Illness: A Systematic Review and Meta-Analysis. Prim Care Companion CNS Disord [Internet]. 2019 Dec 19;21(6). Available from:](http://paperpile.com/b/oQGKXB/n7du) <http://dx.doi.org/10.4088/PCC.19r02483>

42. [Brown C, Geiszler LC, Lewis KJ, Arbesman M. Effectiveness of Interventions for Weight Loss for People With Serious Mental Illness: A Systematic Review and Meta-Analysis. Am J Occup Ther. 2018 Sep 1;72(5):7205190030p1–7205190030p9.](http://paperpile.com/b/oQGKXB/GFMm)

43. [Chacón F, Mora F, Gervás-Ríos A, Gilaberte I. Efficacy of lifestyle interventions in physical health management of patients with severe mental illness. Ann Gen Psychiatry. 2011 Sep 19;10(1):1–10.](http://paperpile.com/b/oQGKXB/7VEm)

44. [Henry FJ. Obesity prevention: the key to non-communicable disease control. West Indian Med J. 2011 Jul;60(4):446–51.](http://paperpile.com/b/oQGKXB/O2TG)

45. [Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology. 2007 May;132(6):2087–102.](http://paperpile.com/b/oQGKXB/twcZ)

46. [Vincze L, Barnes K, Somerville M, Littlewood R, Atkins H, Rogany A, et al. Cultural adaptation of health interventions including a nutrition component in Indigenous peoples: a systematic scoping review. Int J Equity Health. 2021 May 22;20(1):125.](http://paperpile.com/b/oQGKXB/8xs4)

47. [Malik VS, Willet WC, Hu FB. Nearly a decade on — trends, risk factors and policy implications in global obesity [Internet]. Vol. 16, Nature Reviews Endocrinology. 2020. p. 615–6. Available from:](http://paperpile.com/b/oQGKXB/Katm) <http://dx.doi.org/10.1038/s41574-020-00411-y>

48. [Ford ND, Patel SA, Narayan KMV. Obesity in Low- and Middle-Income Countries: Burden, Drivers, and Emerging Challenges. Annu Rev Public Health. 2017 Mar 20;38:145–64.](http://paperpile.com/b/oQGKXB/nrD9)

49. [Chandel RK, Resident S, Postgraduate Department of psychiatry, Institute of Mental Health and Neuroscience, Mushtaq R, Shoib S. Prevalence of metabolic syndrome in drug naïve bipolar affective disorders- A study from South East Asia (Kashmir) [Internet]. Vol. 2, International Journal of Scientific Research. 2012. p. 395–8. Available from:](http://paperpile.com/b/oQGKXB/gjkx) <http://dx.doi.org/10.15373/22778179/dec2013/119>

50. [Kessing LV. Gender differences in the phenomenology of bipolar disorder. Bipolar Disord. 2004 Oct;6(5):421–5.](http://paperpile.com/b/oQGKXB/3KWs)

51. [Li Q, Chen D, Liu T, Walss-Bass C, de Quevedo JL, Soares JC, et al. Sex Differences in Body Mass Index and Obesity in Chinese Patients With Chronic Schizophrenia. J Clin Psychopharmacol. 2016 Dec;36(6):643–8.](http://paperpile.com/b/oQGKXB/BZiE)

52. [Richardson CR, Faulkner G, McDevitt J, Skrinar GS, Hutchinson DS, Piette JD. Integrating physical activity into mental health services for persons with serious mental illness. Psychiatr Serv. 2005 Mar;56(3):324–31.](http://paperpile.com/b/oQGKXB/hMUD)

53. [Pastrana T, Vallath N, Mastrojohn J, Namukwaya E, Kumar S, Radbruch L, et al. Disparities in the contribution of low- and middle-income countries to palliative care research. J Pain Symptom Manage. 2010 Jan;39(1):54–68.](http://paperpile.com/b/oQGKXB/6V19)

54. [Keating EM, Haq H, Rees CA, Dearden KA, Luboga SA, Schutze GE, et al. Global Disparities Between Pediatric Publications and Disease Burden From 2006 to 2015. Glob Pediatr Health. 2019 Feb 25;6:2333794X19831298.](http://paperpile.com/b/oQGKXB/6J3G)

55. [Rathod S, Pinninti N, Irfan M, Gorczynski P, Rathod P, Gega L, et al. Mental Health Service Provision in Low- and Middle-Income Countries. Health Serv Insights. 2017 Mar 28;10:1178632917694350.](http://paperpile.com/b/oQGKXB/wM05)

56. [Zavala GA, Haidar A, Prasad-Muliyala K, Aslam F, Huque R, Khalid H, et al. The physical health of people with severe mental illness in Bangladesh and Pakistan: A cross-sectional survey [Internet]. Research Square; 2021. Available from:](http://paperpile.com/b/oQGKXB/JFAG) <https://www.researchsquare.com/article/rs-429162/latest.pdf>

# Tables

**Table 1.** Summary of the studies

|  |  |  |
| --- | --- | --- |
| **Variable** | **N (120)** | **Percentage** |
| **World Bank classification** |  |  |
| HICs | 95 | 79.1% |
| LMICs | 25 | 20.1% |
| **World Bank region** |  |  |
| Sub Saharan Africa | 3 | 2.4% |
| East Asia and Pacific | 32 | 25.8% |
| North America | 31 | 25% |
| Europe and Central Asia | 45 | 36.3% |
| South Asia | 5 | 4.0% |
| Middle East and North Africa | 2 | 1.6% |
| Latin America and Caribbean | 6 | 4.8% |
| **Type of SMI** |  |  |
| Any SMI**1** | 27 | 22.5% |
| Schizophrenia**2** | 71 | 59.1% |
| Bipolar Disorder | 22 | 18.3% |
| **Setting** |  |  |
| Inpatient | 33 | 26.6% |
| Outpatient | 61 | 49.2% |
| In- and Outpatient | 24 | 19.4% |
| Community | 6 | 4.8% |
| **Antipsychotic medication** |  |  |
| Prescribed antipsychotic medication 3 | 111 | 89.5% |
| Antipsychotic-naive population | 7 | 5.6% |
| Not reported | 6 | 4.8% |
| **SMI diagnostic tool** |  |  |
| DSM | 78 | 65.0% |
| ICD | 18 | 15.0% |
| DSM and ICD | 3 | 2.5% |
| Not specified | 21 | 17.5% |
| **Study design** |  |  |
| Cross-sectional | 110 | 91.6% |
| Cohort | 6 | 5.0% |
| Prospective longitudinal | 4 | 3.3% |
| **Year of data collection** |  |  |
| 1990 - 1999 | 1 | 0.8% |
| 2000 - 2009 | 39 | 32.5% |
| 2010 - Date | 80 | 66.6% |
| **BMI classification** |  |  |
| World Health Organization | 109 | 90.8% |
| Taiwan standards | 3 | 2.5% |
| Japanese Society for the Study of Obesity | 3 | 2.5% |
| Indonesian Standards | 1 | 0.8% |
| Working Group on Obesity China | 1 | 0.8% |
| Asia Standard Scale | 3 | 2.4% |
| **Overall risk of bias** | | |
| Low | 70 | 58.3% |
| Medium | 27 | 22.5% |
| High | 23 | 19.1% |
| HIC: High income country, LMIC: Low- and middle-income countries, SMI: Severe mental illness. 1The “any” category includes studies where the estimates of obesity were not separated between the type SMI; 2we did not find studies focusing on major depression with psychotic features independently and only found one study focusing at first episode of psychosis which was included in the “schizophrenia” category; 3 Studies including participants with prescribed antipsychotic medication or open population (mix of participants taking and not taking antipsychotic medication). | | |

**Table 2.** Pooled prevalence of overweight obesity and combined overweight and obesity according to SMI, geographical region, World Bank classification and year of publication.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Overweight** | **Obesity** | **Combined prevalence of overweight and obesity** |
| Number of studies | 108 | 120 | 108 |
| Overall pooled prevalence (95%CI) | 31.2% (28.9-32.1) | 25.9% (23.3-29.1) | 60.1% (55.8-63.1) |
| Heterogeneity I2 | 97.1% | 88.3% | 98.1% |
| *T*2 | 0.11 | 0.55 | 0.47 |
| P | <0.01 | <0.01 | <0.01 |
| **Type of SMI** |  |  |  |
| Any SMI**1** | 32.9% (31.2-34.7) | 25.4% (20.1-31.7) | 61.2% (56.3-65.7) |
| Bipolar disorder | 31.1% (28.8-33.8) | 27.5% (22.6-33.1) | 60.7% (55.8-65.2) |
| Schizophrenia | 29.8% (27.4-32.2) | 25.5% (22.2-29.3) | 58.6% (53.5-63.6) |
| **Setting** |  |  |  |
| Inpatient | 31.2% (28.2-33.9) | 25.9% (21.1-31.5) | 60.1% (54.4-67.2) |
| Outpatient | 30.1% (28.4-33.1) | 25.9% (22.4-30.1) | 58.8% (53.8-65.1) |
| In- and outpatient | 31.4% (29.1-34.3) | 23.8% (18.6-29.9) | 58.5% (51.8-65.1) |
| Community | 29.8% (26.6-33.9) | 32.8% (25.2-41.8) | 63.2% (55.3-70.5) |
| **Antipsychotic medication** |  |  |  |
| Prescribed antipsychotic medication 2 | 30.6% (29.4-32.1) | 25.8% (23.1-28.8) | 59.3% (55.8-62.6) |
| Antipsychotic-naive population | 34.7% (32.2-37.4) | 33.7% (24.8-43.8) | 68.2% (59.7-75.7) |
| Not reported | 30.9% (19.2-45.7) | 18.8% (13.1-28.7) | 53.7% (37.7-69.0) |
| **World Bank Region** |  |  |  |
| East Asia and Pacific | 28.4% (25.4-31.6) | 22.5% (17.9-27.1) | 53.8% (46.8-60.9) |
| East Asia and Pacific (WHO)3 | 28.2% (24.7-32.3) | 18.1% (14.6-24.1) | 51.2% (44.3-59.3) |
| Europe and Central Asia | 31.9% (28.9-35.1) | 27.5% (22.9-32.6) | 63.1% (56.3-69.7) |
| Latin America & Caribbean | 34.5% (31.6-37.5) | 31.7% (29.2-34.6) | 65.2% (60.0-70.1) |
| Middle East and North Africa | 34.2% (25.5-44.2) | 35.8% (23.8-44.8) | 71.4% (67.8-74.7) |
| North America | 31.1% (29.1-33.9) | 30% (25.4-35.1) | 62.8% (58.2-66.9) |
| South Asia | 31.1% (21.7-41.3) | 17.7% (10.5-28.5) | 51.3% (40.9-61.6) |
| Sub-Saharan Africa | 33.1% (27.8-38.7) | 13.4% (6.7-25.1) | 47.9% (43.7-52.3) |
| **World Bank Classification** |  |  |  |
| HICs | 30.0% (29.1-32.1) | 27.1% (24.1-29.9) | 60.7% (56.9-64.2) |
| LMICs | 32.1% (29.7-35.2) | 22.4% (17.2-27.3) | 55.7% (49.5-61.7) |
| **Year of data collection** |  |  |  |
| 2005 and Older | 27.2% (22.9-31.9) | 20.4% (12.8-30.8) | 51.1% (38.3-63.8) |
| 2006 - 2010 | 33.2% (30.0-36.6) | 30.6% (25.8-35.8) | 66.0% (60.5-71.1) |
| 2011 - 2015 | 30.6% (28.2-33.2) | 27.2% (24.8-31.1) | 59.5% (54.6-64.1) |
| 2016 - Date | 29.5% (27.2-32.8) | 22.4% (17.2-29.6) | 55.3% (48.9-61.5) |
| 1The “any” category includes studies where the estimates of obesity were not separated between the type SMI, we did not find studies looking at major depression with psychotic features independently and only found one study looking at first episode of psychosis which was included in the “schizophrenia” category; 2 Studies including participants with prescribed antipsychotic medication or open population (mix of participants taking and not taking antipsychotic medication);3 Prevalence from the sensitivity analysis excluding papers with cut-of scores different than the WHO. | | | |

**Table 3.** Odds of people with SMI of having overweight and obesity as compared with the general population

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Number of studies** | **N people with SMI** | **N General population** | **Odds ratio** | **95% CI**1 | **p** | **I2** 2 | ***T*2** 3 |
| Overweight | 21 | 6478 | 78937 | 1.07 | 0.91-1.27 | <0.01 | 81% | 0.11 |
| Obesity | 24 | 7165 | 83033 | 3.04 | 2.42 - 3.82 | <0.01 | 91% | 0.42 |
| Overweight and obesity | 21 | 6478 | 78937 | 2.03 | 1.60-2.59 | <0.01 | 92% | 0.27 |
| 1 95% confidence interval; 2 I squared test for heterogeneity; 3Tau squared test for heterogeneity | | | | | | | | |

# Figures

**Figure 1** PRISMA Flow chart

Diagram

Description automatically generated

**Figure 2** Prevalence of obesity in people with SMI

Chart, box and whisker chart

Description automatically generated

**Figure 3** Map of the prevalence of obesity in people with SMI

Map

Description automatically generated

**Figure 4** Trend of obesity

Chart

Description automatically generated

**Figure 5** Odds of people with SMI of having obesity as c compared with the general population Chart, box and whisker chart

Description automatically generated

**This is an electronic supplementary material accompanying the paper “Prevalence of overweight and obesity in people with severe mental illness: systematic review and meta analysis”**

**Supplementary Table 1.** Characteristics of the eligible studies

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Sample size** | **SMIa** | **Setting** | **Country** | **WB region** | **WB income classification** | **Study design** | **Comparison with the general population** | **Comparison Males and Females** | **Overall risk of bias** |
| Silversone 1988 [(1)](https://paperpile.com/c/3JPyg8/WFk4) | 226 | Schizophrenia | Outpatient | England | Europe & Central Asia | HIC | Cross-sectional | No | Yes | Medium |
| Elmslie 2000 [(2)](https://paperpile.com/c/3JPyg8/IbKa) | 89 | Bipolar disorders | Out and Inpatient | New Zealand | East Asia & Pacific | HIC | Cross-sectional | Yes | Yes | Low |
| Coodin 2001 [(3)](https://paperpile.com/c/3JPyg8/ax5V) | 183 | Schizophrenia | Inpateint | Canada | North America | HIC | Cross-sectional | Yes | No | High |
| Davidson 2001 [(4)](https://paperpile.com/c/3JPyg8/m6UI) | 234 | Any | Outpatient | Australia | East Asia & Pacific | HIC | Cross-sectional | Yes | Yes | High |
| Winkelman 2001 [(5)](https://paperpile.com/c/3JPyg8/W5VZ) | 46 | Schizophrenia | Outpatient | US | North America | HIC | Cross-sectional | No | No | Medium |
| Winkelman 2001 [(5)](https://paperpile.com/c/3JPyg8/W5VZ) | 92 | Bipolar disorders | Outpatient | US | North America | HIC | Cross-sectional | No | No | Medium |
| Strassnig 2003 [(6)](https://paperpile.com/c/3JPyg8/LxbK) | 146 | Schizophrenia | Outpatient | US | North America | HIC | Cross-sectional | No | No | Low |
| Daumit 2003 [(7)](https://paperpile.com/c/3JPyg8/aqlu) | 223 | Any | Inpateint | US | North America | HIC | Cross-sectional | Yes | Yes | High |
| Hsiao 2004 [(8)](https://paperpile.com/c/3JPyg8/GLSP) | 201 | Schizophrenia | Outpatient | Taiwan | East Asia & Pacific | LMIC | Cross-sectional | Yes | Yes | High |
| Strassnig 2005 [(9)](https://paperpile.com/c/3JPyg8/x7wX) | 143 | Schizophrenia | Outpatient | US | North America | HIC | Cross-sectional | No | No | Low |
| Fagiolini 2005 [(10)](https://paperpile.com/c/3JPyg8/jlh6) | 171 | Bipolar disorders | Outpatient | US | North America | HIC | Cross-sectional | No | No | Low |
| Wang 2006 [(11)](https://paperpile.com/c/3JPyg8/cvvW) | 377 | Bipolar disorders | Community | US | North America | HIC | Cross-sectional | No | Yes | High |
| DeHert 2006 [(12)](https://paperpile.com/c/3JPyg8/wBLd) | 300 | Any | Out and Inpatient | Belgium | Europe & Central Asia | HIC | Cross-sectional | No | No | High |
| Dickerson 2006 [(13)](https://paperpile.com/c/3JPyg8/xla1) | 169 | Any | Outpatient | US | North America | HIC | Cross-sectional | Yes | Yes | Low |
| Faulkner 2007 [(14)](https://paperpile.com/c/3JPyg8/pS4H) | 90 | Schizophrenia | Inpateint | Canada | North America | HIC | Cross-sectional | No | No | Low |
| Henderson 2006 [(15)](https://paperpile.com/c/3JPyg8/WLQW) | 88 | Schizophrenia | Out and Inpatient | US | North America | HIC | Cross-sectional | No | No | High |
| Kitabayashi 2006 [(16)](https://paperpile.com/c/3JPyg8/KLPb) | 273 | Schizophrenia | Inpateint | Japan | East Asia & Pacific | HIC | Cross-sectional | Yes | Yes | Low |
| Leitao-azevedo 2006 [(17)](https://paperpile.com/c/3JPyg8/Uh1h) | 121 | Schizophrenia | Outpatient | Brazil | Latin America & Carribean | HIC | Cross-sectional | No | No | Low |
| Feeney 2007 [(18)](https://paperpile.com/c/3JPyg8/sVIc) | 122 | Schizophrenia | Out and Inpatient | Ireland | Europe & Central Asia | HIC | Cross-sectional | No | No | Medium |
| Hellerstein 2007 [(19)](https://paperpile.com/c/3JPyg8/UdZY) | 69 | Schizophrenia | Outpatient | England | Europe & Central Asia | HIC | Cross-sectional | No | Yes | Medium |
| Kim 2008 [(20)](https://paperpile.com/c/3JPyg8/CNUI) | 179 | Bipolar disorders | Inpateint | South Korea | East Asia & Pacific | HIC | Cross-sectional | No | No | Medium |
| Mackin 2007 [(21)](https://paperpile.com/c/3JPyg8/5A5h) | 106 | Any | Outpatient | England | Europe & Central Asia | HIC | Cross-sectional | No | Yes | Low |
| Nishiyama 2007 [(22)](https://paperpile.com/c/3JPyg8/vgrR) | 208 | Schizophrenia | Inpateint | Japan | East Asia & Pacific | HIC | Cross-sectional | Yes | Yes | Medium |
| Tirupati 2007 [(23)](https://paperpile.com/c/3JPyg8/NRi2) | 221 | Any | Out and Inpatient | Australia | East Asia & Pacific | HIC | Cross-sectional | No | No | High |
| Maina 2008 [(24)](https://paperpile.com/c/3JPyg8/ndYc) | 76 | Bipolar disorders | Out and Inpatient | Italy | Europe & Central Asia | HIC | Cross-sectional | No | No | High |
| Ainsah 2008 [(25)](https://paperpile.com/c/3JPyg8/yWpy) | 97 | Schizophrenia | Outpatient | Malaysia | East Asia & Pacific | LMIC | Cross-sectional | No | No | High |
| Correll 2008 [(26)](https://paperpile.com/c/3JPyg8/Etl1) | 185 | Any | Inpateint | US | North America | HIC | Cross-sectional | No | No | High |
| Limosin 2008 [(27)](https://paperpile.com/c/3JPyg8/2FIv) | 5962 | Schizophrenia | Out and Inpatient | France | Europe & Central Asia | HIC | Cross-sectional | No | Yes | Low |
| McLaren 2008 [(28)](https://paperpile.com/c/3JPyg8/bdBM) | 5137 | Any | Out and Inpatient | Canada | North America | HIC | Cross-sectional | No | No | Medium |
| VanWinkel 2008 [(29)](https://paperpile.com/c/3JPyg8/CXkz) | 60 | Bipolar disorders | Outpatient | Belgium | Europe & Central Asia | HIC | Cross-sectional | No | No | High |
| Calkin 2009 [(30)](https://paperpile.com/c/3JPyg8/2WTk) | 276 | Bipolar disorders | Inpateint | Canada | North America | HIC | Cross-sectional | No | No | Medium |
| Bell 2009 [(31)](https://paperpile.com/c/3JPyg8/cDmN) | 819 | Schizophrenia | Outpatient | US | North America | HIC | Cross-sectional | No | No | Low |
| Bernado 2009 [(32)](https://paperpile.com/c/3JPyg8/9VVm) | 733 | Schizophrenia | Inpateint | Spain | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Boden 2009 [(33)](https://paperpile.com/c/3JPyg8/0Njp) | 59 | Schizophrenia | Outpatient | Sweden | Europe & Central Asia | HIC | Cohort | No | No | Low |
| deAlmeida 2009 [(34)](https://paperpile.com/c/3JPyg8/xV1z) | 84 | Bipolar disorders | Outpatient | Brazil | Latin America & Carribean | LMIC | Cross-sectional | No | No | Medium |
| Fiedorowicz 2008 [(35)](https://paperpile.com/c/3JPyg8/TQkj) | 217 | Bipolar disorders | Inpateint | US | North America | HIC | Cross-sectional | Yes | No | High |
| Huang 2009 [(36)](https://paperpile.com/c/3JPyg8/NJk8) | 650 | Schizophrenia | Inpateint | Taiwan | East Asia & Pacific | LMIC | Cross-sectional | No | Yes | Low |
| UmaDevi 2009 [(37)](https://paperpile.com/c/3JPyg8/nXRp) | 60 | Schizophrenia | Inpateint | India | South Asia | LMIC | Cross-sectional | No | No | High |
| Vancampfort 2011 [(38)](https://paperpile.com/c/3JPyg8/E3I2) | 60 | Schizophrenia | Inpateint | Belgium | Europe & Central Asia | HIC | Cross-sectional | No | No | High |
| Correll 2010 [(39)](https://paperpile.com/c/3JPyg8/ErP7) | 10084 | Any | Outpatient | US | North America | HIC | Cross-sectional | No | No | Low |
| Lee 2010 [(40)](https://paperpile.com/c/3JPyg8/zl2u) | 152 | Bipolar disorders | Out and Inpatient | South Korea | East Asia & Pacific | HIC | Cross-sectional | Yes | Yes | Low |
| Mahendran 2010 [(41)](https://paperpile.com/c/3JPyg8/brfa) | 266 | Schizophrenia | Outpatient | Singapore | East Asia & Pacific | HIC | Cohort | No | Yes | High |
| Arango 2011 [(42)](https://paperpile.com/c/3JPyg8/rfEw) | 1452 | Schizophrenia | Outpatient | Spain | Europe & Central Asia | HIC | Cross-sectional | No | No | Medium |
| Chu 2011 [(43)](https://paperpile.com/c/3JPyg8/dCe9) | 878 | Schizophrenia | Inpateint | Taiwan | East Asia & Pacific | LMIC | Cross-sectional | No | No | Low |
| Falissard 2011 [(44)](https://paperpile.com/c/3JPyg8/QOgK) | 484 | Schizophrenia | Outpatient | Bulgaria | Europe & Central Asia | LMIC | Cross-sectional | No | No | Low |
| Falissard 2011 [(44)](https://paperpile.com/c/3JPyg8/QOgK) | 163 | Schizophrenia | Outpatient | Czech Republic | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Falissard 2011 [(44)](https://paperpile.com/c/3JPyg8/QOgK) | 106 | Schizophrenia | Outpatient | Estonia | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Falissard 2011 [(44)](https://paperpile.com/c/3JPyg8/QOgK) | 57 | Schizophrenia | Outpatient | Germany | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Falissard 2011 [(44)](https://paperpile.com/c/3JPyg8/QOgK) | 261 | Schizophrenia | Outpatient | Greece | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Falissard 2011 [(44)](https://paperpile.com/c/3JPyg8/QOgK) | 145 | Schizophrenia | Outpatient | Italy | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Falissard 2011 [(44)](https://paperpile.com/c/3JPyg8/QOgK) | 119 | Schizophrenia | Outpatient | Latvia | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Falissard 2011 [(44)](https://paperpile.com/c/3JPyg8/QOgK) | 195 | Schizophrenia | Outpatient | Lithuania | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Falissard 2011 [(44)](https://paperpile.com/c/3JPyg8/QOgK) | 92 | Schizophrenia | Outpatient | Romania | Europe & Central Asia | LMIC | Cross-sectional | No | No | Low |
| Falissard 2011 [(44)](https://paperpile.com/c/3JPyg8/QOgK) | 383 | Schizophrenia | Outpatient | Russia | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Falissard 2011 [(44)](https://paperpile.com/c/3JPyg8/QOgK) | 91 | Schizophrenia | Outpatient | Slovenia | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Falissard 2011 [(44)](https://paperpile.com/c/3JPyg8/QOgK) | 174 | Schizophrenia | Outpatient | Turkey | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Goldstein 2011 [(45)](https://paperpile.com/c/3JPyg8/yAOe) | 43093 | Bipolar disorders | Outpatient | US | North America | HIC | Cohort | No | No | Low |
| McElroy 2011 [(46)](https://paperpile.com/c/3JPyg8/J5IJ) | 875 | Bipolar disorders | Community | UK | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Mookhoek 2011 [(47)](https://paperpile.com/c/3JPyg8/X3PT) | 256 | Schizophrenia | Inpateint | The Netherlands | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Udo 2011 [(48)](https://paperpile.com/c/3JPyg8/ATTw) | 30 | Any | Inpateint | Ireland | Europe & Central Asia | HIC | Cross-sectional | No | No | High |
| Inamura 2012 [(49)](https://paperpile.com/c/3JPyg8/9F8k) | 15171 | Schizophrenia | Inpateint | Japan | East Asia & Pacific | HIC | Cross-sectional | No | Yes | Low |
| Centorrino 2012 [(50)](https://paperpile.com/c/3JPyg8/r673) | 76 | Schizophrenia | Inpateint | US | North America | HIC | Cross-sectional | No | No | Low |
| Centorrino 2012 [(50)](https://paperpile.com/c/3JPyg8/r673) | 173 | Bipolar disorders | Inpateint | US | North America | HIC | Cross-sectional | No | No | Low |
| Choong 2012 [(51)](https://paperpile.com/c/3JPyg8/YNi2) | 196 | Schizophrenia | Outpatient | Switzerland | Europe & Central Asia | HIC | Cross-sectional | No | Yes | Low |
| Feiler 2012 [(52)](https://paperpile.com/c/3JPyg8/LNNP) | 106 | Any | Inpateint | Australia | East Asia & Pacific | HIC | Cross-sectional | Yes | Yes | Low |
| Galletly 2012 [(53)](https://paperpile.com/c/3JPyg8/kFjb) | 1286 | Any | Community | Australia | East Asia & Pacific | HIC | Cross-sectional | No | Yes | Low |
| Gurpegui 2012 [(54)](https://paperpile.com/c/3JPyg8/v87x) | 648 | Bipolar disorders | Outpatient | Spain | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Gurpegui 2012 [(54)](https://paperpile.com/c/3JPyg8/v87x) | 648 | Schizophrenia | Outpatient | Spain | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Lan 2012 [(55)](https://paperpile.com/c/3JPyg8/ZEjd) | 1030 | Schizophrenia | Inpateint | Taiwan | East Asia & Pacific | LMIC | Cross-sectional | No | Yes | Low |
| Lee 2012 [(56)](https://paperpile.com/c/3JPyg8/EKwj) | 100 | Schizophrenia | Out and Inpatient | Singapore | East Asia & Pacific | HIC | Cross-sectional | Yes | Yes | Low |
| Schuster 2012 [(57)](https://paperpile.com/c/3JPyg8/EMxw) | 3714 | Schizophrenia | Outpatient | France | Europe & Central Asia | HIC | Propective Longitudinal | No | No | Medium |
| Janney 2014 [(58)](https://paperpile.com/c/3JPyg8/dj3z) | 60 | Bipolar disorders | Community | US | North America | HIC | Cross-sectional | No | Yes | Medium |
| Sugawara 2013 [(59)](https://paperpile.com/c/3JPyg8/x85U) | 225 | Schizophrenia | Outpatient | Japan | East Asia & Pacific | HIC | Cross-sectional | No | Yes | Low |
| Bener 2014 [(60)](https://paperpile.com/c/3JPyg8/bLlL) | 233 | Schizophrenia | Outpatient | Qatar | Middle East & North Africa | HIC | Cross-sectional | Yes | Yes | Medium |
| Gordan 2012 [(61)](https://paperpile.com/c/3JPyg8/iOKF) | 261 | Schizophrenia | Outpatient | Brazil | Latin America & Carribean | LMIC | Cross-sectional | No | Yes | High |
| Guo 2013 [(62)](https://paperpile.com/c/3JPyg8/bZlr) | 1108 | Schizophrenia | Outpatient | China | East Asia & Pacific | LMIC | Cross-sectional | No | No | Low |
| Minsky 2013 [(63)](https://paperpile.com/c/3JPyg8/C5sb) | 586 | Any | Out and Inpatient | US | North America | HIC | Cross-sectional | No | No | High |
| Nunes 2014 [(64)](https://paperpile.com/c/3JPyg8/1tLH) | 25 | Schizophrenia | Outpatient | Brazil | Latin America & Carribean | HIC | Cross-sectional | Yes | Yes | Low |
| Suzuki 2013 [(65)](https://paperpile.com/c/3JPyg8/TKVZ) | 171 | Schizophrenia | Inpateint | Japan | East Asia & Pacific | HIC | Cohort | No | No | Medium |
| Depp 2014 [(66)](https://paperpile.com/c/3JPyg8/4FBQ) | 358 | Schizophrenia | Outpatient | US | North America | HIC | Cross-sectional | No | No | Low |
| Depp 2014 [(66)](https://paperpile.com/c/3JPyg8/4FBQ) | 400 | Bipolar disorders | Outpatient | US | North America | HIC | Cross-sectional | No | No | Low |
| Foldemo 2014 [(67)](https://paperpile.com/c/3JPyg8/uMYY) | 903 | Schizophrenia | Outpatient | Sweden | Europe & Central Asia | HIC | Cross-sectional | Yes | Yes | Medium |
| Post 2014 [(68)](https://paperpile.com/c/3JPyg8/rJdM) | 165 | Bipolar disorders | Outpatient | Germany | Europe & Central Asia | HIC | Propective Longitudinal | No | No | Medium |
| Post 2014 [(68)](https://paperpile.com/c/3JPyg8/rJdM) | 166 | Bipolar disorders | Outpatient | The Netherlands | Europe & Central Asia | HIC | Propective Longitudinal | No | No | Medium |
| Post 2014 [(68)](https://paperpile.com/c/3JPyg8/rJdM) | 676 | Bipolar disorders | Outpatient | US | North America | HIC | Propective Longitudinal | No | No | Medium |
| Subramaniam 2014 [(69)](https://paperpile.com/c/3JPyg8/goc8) | 973 | Schizophrenia | Outpatient | Singapore | East Asia & Pacific | HIC | Cross-sectional | Yes | Yes | Low |
| Suzuki 2014 [(70)](https://paperpile.com/c/3JPyg8/AOFI) | 333 | Schizophrenia | Inpateint | Japan | East Asia & Pacific | HIC | Cross-sectional | Yes | Yes | Medium |
| Ventriglio 2014 [(71)](https://paperpile.com/c/3JPyg8/6CEE) | 66 | Any | Outpatient | Italy | Europe & Central Asia | HIC | Cross-sectional | No | No | Low |
| Bernstein 2015 [(72)](https://paperpile.com/c/3JPyg8/cHOE) | 62 | Bipolar disorders | Outpatient | US | North America | HIC | Cross-sectional | No | No | High |
| Marthoenis 2014 [(73)](https://paperpile.com/c/3JPyg8/itIJ) | 86 | Schizophrenia | Inpateint | Indonesia | East Asia & Pacific | LMIC | Cross-sectional | No | No | Medium |
| Sugai 2015 [(74)](https://paperpile.com/c/3JPyg8/YLrk) | 19678 | Schizophrenia | Out and Inpatient | Japan | East Asia & Pacific | HIC | Cross-sectional | No | No | Low |
| Bioque 2018 [(75)](https://paperpile.com/c/3JPyg8/KuoP) | 335 | Schizophrenia | Out and Inpatient | Spain | Europe & Central Asia | HIC | Cross-sectional | Yes | Yes | Low |
| Chouinard 2016 [(76)](https://paperpile.com/c/3JPyg8/yvk0) | 262 | Any | Inpateint | US | North America | HIC | Cross-sectional | No | No | Low |
| Lopuszanska 2016 [(77)](https://paperpile.com/c/3JPyg8/fXw3) | 91 | Any | Inpateint | Poland | Europe & Central Asia | HIC | Cross-sectional | No | Yes | Low |
| McElroy 2016 [(78)](https://paperpile.com/c/3JPyg8/jrJQ) | 1114 | Bipolar disorders | Community | UK | Europe & Central Asia | HIC | Cross-sectional | No | No | Medium |
| Annamalai 2017 [(79)](https://paperpile.com/c/3JPyg8/ZrKM) | 326 | Schizophrenia | Outpatient | US | North America | HIC | Cohort | Yes | Yes | Medium |
| Najar 2017 [(80)](https://paperpile.com/c/3JPyg8/NWzc) | 1141 | Any | Outpatient | Sweden | Europe & Central Asia | HIC | Cross-sectional | No | No | Medium |
| Oh 2017 [(81)](https://paperpile.com/c/3JPyg8/BHX8) | 167 | Schizophrenia | Inpateint | South Korea | East Asia & Pacific | HIC | Cross-sectional | No | No | Low |
| Susilova 2017 [(82)](https://paperpile.com/c/3JPyg8/ERGV) | 462 | Schizophrenia | Inpateint | Czech Republic | Europe & Central Asia | HIC | Propective Longitudinal | No | Yes | High |
| Berti 2018 [(83)](https://paperpile.com/c/3JPyg8/1YQq) | 193 | Schizophrenia | Outpatient | Italy | Europe & Central Asia | HIC | Cross-sectional | Yes | Yes | High |
| Blomqvist 2019 [(84)](https://paperpile.com/c/3JPyg8/rrDb) | 57 | Schizophreni | Outpatient | Sweden | Europe & Central Asia | HIC | Cross-sectional | No | No | High |
| Asaye 2018 [(85)](https://paperpile.com/c/3JPyg8/vZrL) | 360 | Any | Out and Inpatient | Ethiopia | Africa | LMIC | Cross-sectional | No | No | Low |
| Aziz 2018 [(86)](https://paperpile.com/c/3JPyg8/8p7Q) | 50 | Schizophrenia | Outpatient | Pakistan | South Asia | LMIC | Cross-sectional | No | No | High |
| Iruretagoyena 2018 [(87)](https://paperpile.com/c/3JPyg8/7ytJ) | 148 | Schizophrenia | Out and Inpatient | Chile | Latin America & Carribean | HIC | Cross-sectional | Yes | Yes | Low |
| Zhao 2018 [(88)](https://paperpile.com/c/3JPyg8/PXOZ) | 466 | Schizophrenia | Inpateint | China | East Asia & Pacific | LMIC | Cohort | Yes | Yes | Low |
| deCaluwe 2019 [(89)](https://paperpile.com/c/3JPyg8/bPzA) | 350 | Any | Out and Inpatient | Curaçao | Latin America & Carribean | HIC | Cross-sectional | No | No | Low |
| Tzeng 2020 [(90)](https://paperpile.com/c/3JPyg8/QSf5) | 260 | Any | Inpateint | Taiwan | East Asia & Pacific | LMIC | Cross-sectional | No | No | Medium |
| Vedal 2019 [(91)](https://paperpile.com/c/3JPyg8/MuXy) | 750 | Any | Outpatient | Norway | Europe & Central Asia | HIC | Cross-sectional | Yes | Yes | Low |
| Agaba 2020 [(92)](https://paperpile.com/c/3JPyg8/rxm2) | 304 | Any | Outpatient | Uganda | Africa | LMIC | Cross-sectional | No | No | Medium |
| Hammoudeh 2020 [(93)](https://paperpile.com/c/3JPyg8/sLNV) | 439 | Any | Out and Inpatient | Qatar | Middle East & North Africa | HIC | Cross-sectional | No | No | High |
| Park 2020 [(94)](https://paperpile.com/c/3JPyg8/X609) | 420 | Schizophrenia | Out and Inpatient | India | South Asia | LMIC | Cross-sectional | No | No | Low |
| Park 2020 [(94)](https://paperpile.com/c/3JPyg8/X609) | 463 | Schizophrenia | Out and Inpatient | Indonesia | East Asia & Pacific | LMIC | Cross-sectional | No | No | Low |
| Park 2020 [(94)](https://paperpile.com/c/3JPyg8/X609) | 145 | Schizophrenia | Out and Inpatient | Japan | East Asia & Pacific | HIC | Cross-sectional | No | No | Low |
| Park 2020 [(94)](https://paperpile.com/c/3JPyg8/X609) | 230 | Schizophrenia | Out and Inpatient | Malaysia | East Asia & Pacific | LMIC | Cross-sectional | No | No | Low |
| Park 2020 [(94)](https://paperpile.com/c/3JPyg8/X609) | 184 | Schizophrenia | Out and Inpatient | Taiwan | East Asia & Pacific | LMIC | Cross-sectional | No | No | Low |
| Smith 2016 [(95)](https://paperpile.com/c/3JPyg8/6OM7) | 46 | Any | Outpatient | UK | Europe & Central Asia | HIC | Cross-sectional | No | Yes | Low |
| Teshome 2020 [(96)](https://paperpile.com/c/3JPyg8/E4wL) | 245 | Any | Outpatient | Ethiopia | Africa | LMIC | Cross-sectional | No | No | Medium |
| Wang 2020 [(97)](https://paperpile.com/c/3JPyg8/YaiQ) | 325 | Schizophrenia | Community | China | East Asia & Pacific | LMIC | Cross-sectional | No | Yes | Low |
| Zavala 2020 [(98)](https://paperpile.com/c/3JPyg8/GCmq) | 1500 | Any | Out and Inpatient | Bangladesh | South Asia | LMIC | Cross-sectional | No | No | Low |
| Zavala 2020 [(98)](https://paperpile.com/c/3JPyg8/GCmq) | 858 | Any | Out and Inpatient | Pakistan | South Asia | LMIC | Cross-sectional | No | No | Low |

**Supplementary figure 1.** Funnel plot assessing publication bias

The visual inspection of the funnel plot from the selected studies shown no evidence of publication bias Chart, scatter chart

Description automatically generated

The visual inspection of the funnel plot from the selected studies shown no evidence of publication bias

**List of papers in a language other than English.**

1. Schizophrenia, obesity and pharmacotherapy-associated weight gain [(99)](https://paperpile.com/c/3JPyg8/7HSr).
2. The prevalence of metabolic syndrome and related factors in patients with schizophrenia [(100)](https://paperpile.com/c/3JPyg8/eMyg).
3. The prevalence of obesity and weight gain among the patients with psychotic disorder who use antipsychotic medication, one year follow-up [(101)](https://paperpile.com/c/3JPyg8/bkqM).
4. Metabolic side effects of atypical antipsychotic medication in outpatients of a University Hospital Clinic [(102)](https://paperpile.com/c/3JPyg8/TZYj).
5. Cardiovascular risk factors, cardiovascular risk and quality of life in patients with a severe mental disorder [(103)](https://paperpile.com/c/3JPyg8/qClK).
6. Dietary intake of young Icelanders with psychotic disorders and weight development over an 8-12 months period [(104)](https://paperpile.com/c/3JPyg8/jo6Q).
7. Survey of obesity and underweight among inpatients with schizophrenia in psychiatric hospitals throughout Japan[(105)](https://paperpile.com/c/3JPyg8/mwDm)
8. Prevalence of the metabolic syndrome among schizophrenic patients hospitalized in the Canary Islands [(106)](https://paperpile.com/c/3JPyg8/trom).
9. Disturbi mentali gravi e Sindrome Metabolica: meta-analisi e studio trasversale comparativo [(107)](https://paperpile.com/c/3JPyg8/EtbD).
10. Vigilance level for cardiovascular risk factors in schizophrenic patients [(108)](https://paperpile.com/c/3JPyg8/nVsU).
11. A study of risk factors for cardiovascular disease among schizophrenic patients using the rehabilitation mental health services at Kleppur [(109)](https://paperpile.com/c/3JPyg8/MsUo).
12. Risk factors for inactivity in patients in long-term care with severe mental illness [(110)](https://paperpile.com/c/3JPyg8/Uo3M).
13. Eating disorders in psychiatric patients during treatment with second generation antipsychotics [(111)](https://paperpile.com/c/3JPyg8/K1rD).
14. Body weight changes in chronic psychotic female in-patients [(112)](https://paperpile.com/c/3JPyg8/emf0).
15. Metabolic syndrome in bipolar affective disorder [(113)](https://paperpile.com/c/3JPyg8/PKFg).
16. Weight gain in patients with schizophrenia and schizoaffective disorder under antipsychotic treatment: A three-year naturalistic follow-up study [(114)](https://paperpile.com/c/3JPyg8/Ribf).

**Supplementary material references**

1. [Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry. 1988 Aug;153:214–7.](http://paperpile.com/b/3JPyg8/WFk4)

2. [Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry. 2000 Mar;61(3):179–84.](http://paperpile.com/b/3JPyg8/IbKa)

3. [Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry. 2001 Aug;46(6):549–55.](http://paperpile.com/b/3JPyg8/ax5V)

4. [Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001 Apr;35(2):196–202.](http://paperpile.com/b/3JPyg8/m6UI)

5. [Winkelman JW. Schizophrenia, obesity, and obstructive sleep apnea. J Clin Psychiatry. 2001 Jan;62(1):8–11.](http://paperpile.com/b/3JPyg8/W5VZ)

6. [Strassnig M, Brar JS, Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull. 2003;29(2):393–7.](http://paperpile.com/b/3JPyg8/LxbK)

7. [Daumit GL, Clark JM, Steinwachs DM, Graham CM, Lehman A, Ford DE. Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. J Nerv Ment Dis. 2003 Dec;191(12):799–805.](http://paperpile.com/b/3JPyg8/aqlu)

8. [Hsiao C-C, Ree S-C, Chiang Y-L, Yeh S-S, Chen C-K. Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan. Psychiatry Clin Neurosci. 2004 Aug;58(4):403–9.](http://paperpile.com/b/3JPyg8/GLSP)

9. [Strassnig M, Brar JS, Ganguli R. Self-reported body weight perception and dieting practices in community-dwelling patients with schizophrenia. Schizophr Res. 2005 Jun 15;75(2-3):425–32.](http://paperpile.com/b/3JPyg8/x7wX)

10. [Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005 Oct;7(5):424–30.](http://paperpile.com/b/3JPyg8/jlh6)

11. [Wang PW, Sachs GS, Zarate CA, Marangell LB, Calabrese JR, Goldberg JF, et al. Overweight and obesity in bipolar disorders. J Psychiatr Res. 2006 Dec;40(8):762–4.](http://paperpile.com/b/3JPyg8/cvvW)

12. [De Hert M, Peuskens B, van Winkel R, Kalnicka D, Hanssens L, Van Eyck D, et al. Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE. Schizophr Res. 2006 Dec;88(1-3):222–6.](http://paperpile.com/b/3JPyg8/wBLd)

13. [Dickerson FB, Brown CH, Kreyenbuhl JA, Fang L, Goldberg RW, Wohlheiter K, et al. Obesity among individuals with serious mental illness. Acta Psychiatr Scand. 2006 Apr;113(4):306–13.](http://paperpile.com/b/3JPyg8/xla1)

14. [Faulkner G, Cohn T, Remington G, Irving H. Body mass index, waist circumference and quality of life in individuals with schizophrenia. Schizophr Res. 2007 Feb;90(1-3):174–8.](http://paperpile.com/b/3JPyg8/pS4H)

15. [Henderson DC, Borba CP, Daley TB, Boxill R, Nguyen DD, Culhane MA, et al. Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry. 2006 Apr;18(2):99–105.](http://paperpile.com/b/3JPyg8/WLQW)

16. [Kitabayashi Y, Narumoto J, Kitabayashi M, Fukui K. Body mass index among Japanese inpatients with schizophrenia. Int J Psychiatry Med. 2006;36(1):93–102.](http://paperpile.com/b/3JPyg8/KLPb)

17. [Leitão-Azevedo CL, Abreu MGB de, Guimarães LR, Moreno D, Lobato MI, Gama CS, et al. Overweight and obesity in schizophrenic patients taking clozapine compared to the use of other antipsychotics. Rev psiquiatr Rio Gd Sul. 2006 Aug;28(2):120–8.](http://paperpile.com/b/3JPyg8/Uh1h)

18. [Feeney L, Kelly F, Lee J, Kelly E, McLaughlin S, O’Boyle JH. Point prevalence of diabetes, obesity, hyperlipidaemia, hypertension and smoking in outpatients on clozapine. Ir J Psychol Med. 2007 Jun;24(2):59–61.](http://paperpile.com/b/3JPyg8/sVIc)

19. [Hellerstein DJ, Almeida G, Devlin MJ, Mendelsohn N, Helfand S, Dragatsi D, et al. Assessing obesity and other related health problems of mentally ill Hispanic patients in an urban outpatient setting. Psychiatr Q. 2007 Sep;78(3):171–81.](http://paperpile.com/b/3JPyg8/UdZY)

20. [Kim B, Kim S-J, Son J-I, Joo YH. Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord. 2008 Jan;105(1-3):45–52.](http://paperpile.com/b/3JPyg8/CNUI)

21. [Mackin P, Bishop DR, Watkinson HMO. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry. 2007 Jun 25;7:28.](http://paperpile.com/b/3JPyg8/5A5h)

22. [Nishiyama M, Komahashi T, Kimijima M, Ohrui M. Preliminary report of body mass index among people with and without schizophrenia in Japan. 2007; Available from:](http://paperpile.com/b/3JPyg8/vgrR) <https://dmu.repo.nii.ac.jp/?action=pages_view_main&active_action=repository_view_main_item_detail&item_id=552&item_no=1&page_id=28&block_id=52>

23. [Tirupati S, Chua L-E. Obesity and Metabolic Syndrome in a Psychiatric Rehabilitation Service [Internet]. Vol. 41, Australian & New Zealand Journal of Psychiatry. 2007. p. 606–10. Available from:](http://paperpile.com/b/3JPyg8/NRi2) <http://dx.doi.org/10.1080/00048670701392841>

24. [Maina G, Salvi V, Vitalucci A, D’Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. J Affect Disord. 2008 Sep 1;110(1-2):149–55.](http://paperpile.com/b/3JPyg8/ndYc)

25. [Ainsah O, Salmi R, Osman CB, Shamsul AS. Relationships between antipsychotic medication and anthropometric measurements in patients with schizophrenia attending a psychiatric clinic in Malaysia. East Asian Arch Psychiatry. 2008 Mar;18:23+.](http://paperpile.com/b/3JPyg8/yWpy)

26. [Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008 Nov;10(7):788–97.](http://paperpile.com/b/3JPyg8/Etl1)

27. [Limosin F, Gasquet I, Leguay D, Azorin J-M, Rouillon F. Body mass index and prevalence of obesity in a French cohort of patients with schizophrenia. Acta Psychiatr Scand. 2008 Jul;118(1):19–25.](http://paperpile.com/b/3JPyg8/2FIv)

28. [McLaren L, Beck CA, Patten SB, Fick GH, Adair CE. The relationship between body mass index and mental health. A population-based study of the effects of the definition of mental health. Soc Psychiatry Psychiatr Epidemiol. 2008 Jan;43(1):63–71.](http://paperpile.com/b/3JPyg8/bdBM)

29. [van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord. 2008 Mar;10(2):342–8.](http://paperpile.com/b/3JPyg8/CXkz)

30. [Calkin C, van de Velde C, Růzicková M, Slaney C, Garnham J, Hajek T, et al. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord. 2009 Sep;11(6):650–6.](http://paperpile.com/b/3JPyg8/2WTk)

31. [Bell RC, Farmer S, Ries R, Srebnik D. Metabolic risk factors among medicaid outpatients with schizophrenia receiving second-generation antipsychotics. Psychiatr Serv. 2009 Dec;60(12):1686–9.](http://paperpile.com/b/3JPyg8/cDmN)

32. [Bernardo M, Cañas F, Banegas JR, Casademont J, Riesgo Y, Varela C, et al. Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry. 2009 Oct;24(7):431–41.](http://paperpile.com/b/3JPyg8/9VVm)

33. [Bodén R, Haenni A, Lindström L, Sundström J. Biochemical risk factors for development of obesity in first-episode schizophrenia. Schizophr Res. 2009 Dec;115(2-3):141–5.](http://paperpile.com/b/3JPyg8/0Njp)

34. [de Almeida KM, de Macedo-Soares MB, Kluger Issler C, Antonio Amaral J, Caetano SC, da Silva Dias R, et al. Obesity and metabolic syndrome in Brazilian patients with bipolar disorder. Acta Neuropsychiatr. 2009 Apr;21(2):84–8.](http://paperpile.com/b/3JPyg8/xV1z)

35. [Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry. 2008 Jul;20(3):131–7.](http://paperpile.com/b/3JPyg8/TQkj)

36. [Huang M-C, Lu M-L, Tsai C-J, Chen P-Y, Chiu C-C, Jian D-L, et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand. 2009 Oct;120(4):274–80.](http://paperpile.com/b/3JPyg8/NJk8)

37. [Uma Devi P, Murugam S. Metabolic Disturbances in Schizophrenia Patients With Positive, Negative and Cognitive Symptoms. JK Science [Internet]. 2009;11(3). Available from:](http://paperpile.com/b/3JPyg8/nXRp) <http://www.jkscience.org/archive/vol113/3-Original%20Article%20-%20Metabolic%20Disturbances.pdf>

38. [Vancampfort D, Probst M, Sweers K, Maurissen K, Knapen J, De Hert M. Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia. Acta Psychiatr Scand. 2011 Jun;123(6):423–30.](http://paperpile.com/b/3JPyg8/E3I2)

39. [Correll CU, Druss BG, Lombardo I, O’Gorman C, Harnett JP, Sanders KN, et al. Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv. 2010 Sep;61(9):892–8.](http://paperpile.com/b/3JPyg8/ErP7)

40. [Lee NY, Kim SH, Cho B, Lee YJ, Chang JS, Kang UG, et al. Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea’s general population. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1243–9.](http://paperpile.com/b/3JPyg8/zl2u)

41. [Mahendran R, Hendricks M, Chan YH. Weight gain in Asian patients on second-generation antipsychotics. Ann Acad Med Singapore. 2010 Feb;39(2):118–21.](http://paperpile.com/b/3JPyg8/brfa)

42. [Arango C, Bobes J, Kirkpatrick B, Garcia-Garcia M, Rejas J. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study. Eur Neuropsychopharmacol. 2011 Dec;21(12):867–75.](http://paperpile.com/b/3JPyg8/rfEw)

43. [Chu K-Y, Yang N-P, Chou P, Chi L-Y, Chiu H-J. The relationship between body mass index, the use of second-generation antipsychotics, and dental caries among hospitalized patients with schizophrenia. Int J Psychiatry Med. 2011;41(4):343–53.](http://paperpile.com/b/3JPyg8/dCe9)

44. [Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, et al. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol. 2011 Nov;26(6):291–302.](http://paperpile.com/b/3JPyg8/QOgK)

45. [Goldstein BI, Liu S-M, Zivkovic N, Schaffer A, Chien L-C, Blanco C. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord. 2011 Jun;13(4):387–95.](http://paperpile.com/b/3JPyg8/yAOe)

46. [McElroy SL, Frye MA, Hellemann G, Altshuler L, Leverich GS, Suppes T, et al. Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. J Affect Disord. 2011 Feb;128(3):191–8.](http://paperpile.com/b/3JPyg8/J5IJ)

47. [Mookhoek EJ, de Vries WA, Hovens JEJM, Brouwers JRBJ, Loonen AJM. Risk factors for overweight and diabetes mellitus in residential psychiatric patients. Obes Facts. 2011 Oct 14;4(5):341–5.](http://paperpile.com/b/3JPyg8/X3PT)

48. [Udo I, Mooney M, Newman A. Prevalence of obesity and metabolic syndrome in a long-stay psychiatric unit. Ir J Psychol Med. 2011 Dec;28(4):205–8.](http://paperpile.com/b/3JPyg8/ATTw)

49. [Inamura Y, Sagae T, Nakamachi K, Murayama N. Body mass index of inpatients with schizophrenia in Japan. Int J Psychiatry Med. 2012;44(2):171–81.](http://paperpile.com/b/3JPyg8/9F8k)

50. [Centorrino F, Masters GA, Talamo A, Baldessarini RJ, Öngür D. Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Hum Psychopharmacol. 2012 Sep;27(5):521–6.](http://paperpile.com/b/3JPyg8/r673)

51. [Choong E, Bondolfi G, Etter M, Jermann F, Aubry J-M, Bartolomei J, et al. Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res. 2012 Apr;46(4):540–8.](http://paperpile.com/b/3JPyg8/YNi2)

52. [Feiler G, Chen RC-Y, Pantelis C, Lambert T. Health behaviours of community-treated patients with psychosis. Australas Psychiatry. 2012 Jun;20(3):208–13.](http://paperpile.com/b/3JPyg8/LNNP)

53. [Galletly CA, Foley DL, Waterreus A, Watts GF, Castle DJ, McGrath JJ, et al. Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012 Aug;46(8):753–61.](http://paperpile.com/b/3JPyg8/kFjb)

54. [Gutiérrez-Rojas L, Gurpegui M, Martínez-Ortega JM, Jurado L. Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-Psychiatric Sample [Internet]. Vol. 28, International Clinical Psychopharmacology. 2012. p. e63. Available from:](http://paperpile.com/b/3JPyg8/v87x) <http://dx.doi.org/10.1097/01.yic.0000423356.40365.10>

55. [Lan Y-L, Chen T-L. Prevalence of High Blood Pressure and its Relationship with Body Weight Factors among Inpatients with Schizophrenia in Taiwan. Asian Nurs Res . 2012 Mar;6(1):13–8.](http://paperpile.com/b/3JPyg8/ZEjd)

56. [Lee J, Nurjono M, Wong A, Salim A. Prevalence of metabolic syndrome among patients with schizophrenia in Singapore. Ann Acad Med Singapore. 2012 Oct;41(10):457–62.](http://paperpile.com/b/3JPyg8/EKwj)

57. [Schuster J-P, Raucher-Chéné D, Lemogne C, Rouillon F, Gasquet I, Leguay D, et al. Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia. J Clin Psychopharmacol. 2012 Oct;32(5):672–7.](http://paperpile.com/b/3JPyg8/EMxw)

58. [Janney CA, Fagiolini A, Swartz HA, Jakicic JM, Holleman RG, Richardson CR. Are adults with bipolar disorder active? Objectively measured physical activity and sedentary behavior using accelerometry. J Affect Disord. 2014 Jan;152-154:498–504.](http://paperpile.com/b/3JPyg8/dj3z)

59. [Sugawara N, Yasui-Furukori N, Sato Y, Saito M, Furukori H, Nakagami T, et al. Body mass index and quality of life among outpatients with schizophrenia in Japan. BMC Psychiatry. 2013 Apr 9;13:108.](http://paperpile.com/b/3JPyg8/x85U)

60. [Bener A, Al-Hamaq AOA, Dafeeah EE. A two fold risk of metabolic syndrome in a sample of patients with schizophrenia: Do consanguinity and family history increase risk? [Internet]. Vol. 8, Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2014. p. 24–9. Available from:](http://paperpile.com/b/3JPyg8/bLlL) <http://dx.doi.org/10.1016/j.dsx.2013.10.003>

61. [Gordon P, Louza MR, Xavier. Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia [Internet]. Neuropsychiatric Disease and Treatment. 2013. p. 133. Available from:](http://paperpile.com/b/3JPyg8/iOKF) <http://dx.doi.org/10.2147/ndt.s37019>

62. [Guo X, Zhang Z, Zhai J, Wu R, Liu F, Zhao J, et al. The relationship between obesity and health-related quality of life in Chinese patients with schizophrenia. Int J Psychiatry Clin Pract. 2013 Feb;17(1):16–20.](http://paperpile.com/b/3JPyg8/bZlr)

63. [Minsky S, Vreeland B, Miller M, Gara M. Concordance between measured and self-perceived weight status of persons with serious mental illness. Psychiatr Serv. 2013 Jan;64(1):91–3.](http://paperpile.com/b/3JPyg8/C5sb)

64. [Nunes D, Eskinazi B, Rockett FC, Delgado VB, Perry IDS. Nutritional status, food intake and cardiovascular disease risk in individuals with schizophrenia in southern Brazil: A case–control study [Internet]. Vol. 7, Revista de Psiquiatría y Salud Mental (English Edition). 2014. p. 72–9. Available from:](http://paperpile.com/b/3JPyg8/1tLH) <http://dx.doi.org/10.1016/j.rpsmen.2014.01.001>

65. [Suzuki Y, Mikami T, Tajiri M, Kunizuka T, Abe H, Someya T. Effects of Hospitalization in a Psychiatric Ward on the Body Weight of Japanese Patients with Schizophrenia [Internet]. Vol. 45, The International Journal of Psychiatry in Medicine. 2013. p. 261–8. Available from:](http://paperpile.com/b/3JPyg8/TKVZ) <http://dx.doi.org/10.2190/pm.45.3.e>

66. [Depp CA, Strassnig M, Mausbach BT, Bowie CR, Wolyniec P, Thornquist MH, et al. Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia. Bipolar Disord. 2014 Jun;16(4):422–31.](http://paperpile.com/b/3JPyg8/4FBQ)

67. [Foldemo A, Wärdig R, Bachrach-Lindström M, Edman G, Holmberg T, Lindström T, et al. Health-related quality of life and metabolic risk in patients with psychosis [Internet]. Vol. 152, Schizophrenia Research. 2014. p. 295–9. Available from:](http://paperpile.com/b/3JPyg8/uMYY) <http://dx.doi.org/10.1016/j.schres.2013.11.029>

68. [Post RM, Altshuler LL, Leverich GS, Frye MA, Suppes T, McElroy SL, et al. More medical comorbidities in patients with bipolar disorder from the United States than from the Netherlands and Germany. J Nerv Ment Dis. 2014 Apr;202(4):265–70.](http://paperpile.com/b/3JPyg8/rJdM)

69. [Subramaniam M, Lam M, Guo ME, He VYF, Lee J, Verma S, et al. Body mass index, obesity, and psychopathology in patients with schizophrenia. J Clin Psychopharmacol. 2014 Feb;34(1):40–6.](http://paperpile.com/b/3JPyg8/goc8)

70. [Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Tsuneyama N, et al. High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia. Psychiatry Clin Neurosci. 2014 Jan;68(1):78–82.](http://paperpile.com/b/3JPyg8/AOFI)

71. [Ventriglio A, Gentile A, Baldessarini RJ, Martone S, Vitrani G, La Marca A, et al. Improvements in metabolic abnormalities among overweight schizophrenia and bipolar disorder patients. Eur Psychiatry. 2014 Sep;29(7):402–7.](http://paperpile.com/b/3JPyg8/6CEE)

72. [Bernstein EE, Nierenberg AA, Deckersbach T, Sylvia LG. Eating behavior and obesity in bipolar disorder. Aust N Z J Psychiatry. 2015 Jun;49(6):566–72.](http://paperpile.com/b/3JPyg8/cHOE)

73. [Marthoenis M, Aichberger M, Puteh I, Schouler-Ocak M. Low rate of obesity among psychiatric inpatients in Indonesia. Int J Psychiatry Med. 2014;48(3):175–83.](http://paperpile.com/b/3JPyg8/itIJ)

74. [Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, et al. High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia: a nationwide survey. BMJ Open. 2015 Dec 9;5(12):e008720.](http://paperpile.com/b/3JPyg8/YLrk)

75. [Bioque M, a Paz García-Portilla M, García-Rizo C, Cabrera B, Lobo A, González-Pinto A, et al. Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis [Internet]. Vol. 193, Schizophrenia Research. 2018. p. 188–96. Available from:](http://paperpile.com/b/3JPyg8/KuoP) <http://dx.doi.org/10.1016/j.schres.2017.06.032>

76. [Chouinard V-A, Pingali SM, Chouinard G, Henderson DC, Mallya SG, Cypess AM, et al. Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders. Psychiatry Res. 2016 Mar 30;237:304–10.](http://paperpile.com/b/3JPyg8/yvk0)

77. [Łopuszańska U, Skórzyńska-Dziduszko K, Prendecka M, Makara-Studzińska M. Overweight, obesity and cognitive functions disorders in group of people suffering from mental illness. Psychiatr Pol. 2016;50(2):393–406.](http://paperpile.com/b/3JPyg8/fXw3)

78. [McElroy SL, Crow S, Blom TJ, Cuellar-Barboza AB, Prieto ML, Veldic M, et al. Clinical features of bipolar spectrum with binge eating behaviour. J Affect Disord. 2016 Sep 1;201:95–8.](http://paperpile.com/b/3JPyg8/jrJQ)

79. [Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. World J Diabetes. 2017 Aug 15;8(8):390–6.](http://paperpile.com/b/3JPyg8/ZrKM)

80. [Najar H, Joas E, Kardell M, Pålsson E, Landén M. Weight gain with add-on second-generation antipsychotics in bipolar disorder: a naturalistic study. Acta Psychiatr Scand. 2017 Jun;135(6):606–11.](http://paperpile.com/b/3JPyg8/NWzc)

81. [Oh E, Song E, Shin J. Individual Factors Affecting Self-esteem, and Relationships Among Self-esteem, Body Mass Index, and Body Image in Patients With Schizophrenia. Arch Psychiatr Nurs. 2017 Dec;31(6):588–95.](http://paperpile.com/b/3JPyg8/BHX8)

82. [Sušilová L, Češková E, Hampel D, Sušil A, Šimůnek J. Changes in BMI in hospitalized patients during treatment with antipsychotics, depending on gender and other factors. Int J Psychiatry Clin Pract. 2017 Jun;21(2):112–7.](http://paperpile.com/b/3JPyg8/ERGV)

83. [Berti L, Bonfioli E, Chioffi L, Morgante S, Mazzi MA, Burti L. Lifestyles of Patients with Functional Psychosis Compared to Those of a Sample of the Regional General Population: Findings from a Study in a Community Mental Health Service of the Veneto Region, Italy [Internet]. Vol. 54, Community Mental Health Journal. 2018. p. 1050–6. Available from:](http://paperpile.com/b/3JPyg8/1YQq) <http://dx.doi.org/10.1007/s10597-017-0223-7>

84. [Blomqvist M, Ivarsson A, Carlsson I-M, Sandgren A, Jormfeldt H. Health Risks among People with Severe Mental Illness in Psychiatric Outpatient Settings. Issues Ment Health Nurs. 2018 Jul;39(7):585–91.](http://paperpile.com/b/3JPyg8/rrDb)

85. [Asaye S, Bekele S, Tolessa D, Cheneke W. Metabolic syndrome and associated factors among psychiatric patients in Jimma University Specialized Hospital, South West Ethiopia. Diabetes Metab Syndr. 2018 Sep;12(5):753–60.](http://paperpile.com/b/3JPyg8/vZrL)

86. [Aziz R, Haq AU, Butt BM. Screening for Metabolic Syndrome in Patients on Antipsychotic Medication-A Cross-Sectional Study in a Pakistani Sample. Age. 2018;35:10–9.](http://paperpile.com/b/3JPyg8/8p7Q)

87. [Iruretagoyena B, Castañeda CP, Undurraga J, Nachar R, Mena C, Gallardo C, et al. High prevalence of metabolic alterations in Latin American patients at initial stages of psychosis. Early Interv Psychiatry. 2019 Dec;13(6):1382–8.](http://paperpile.com/b/3JPyg8/7ytJ)

88. [Zhao S, Xia H, Mu J, Wang L, Zhu L, Wang A, et al. 10-year CVD risk in Han Chinese mainland patients with schizophrenia [Internet]. Vol. 264, Psychiatry Research. 2018. p. 322–6. Available from:](http://paperpile.com/b/3JPyg8/PXOZ) <http://dx.doi.org/10.1016/j.psychres.2018.04.020>

89. [Caluwé L de, de Caluwé L, van Buitenen N, Gelan PJ, Crunelle CL, Thomas R, et al. Prevalence of metabolic syndrome and its associated risk factors in an African–Caribbean population with severe mental illness [Internet]. Vol. 281, Psychiatry Research. 2019. p. 112558. Available from:](http://paperpile.com/b/3JPyg8/bPzA) <http://dx.doi.org/10.1016/j.psychres.2019.112558>

90. [Tzeng W-C, Chiang Y-S, Feng H-P, Chien W-C, Tai Y-M, Chen M-J. Gender differences in metabolic syndrome risk factors among patients with serious mental illness. Int J Ment Health Nurs. 2020 Apr;29(2):254–65.](http://paperpile.com/b/3JPyg8/QSf5)

91. [Vedal TSJ, Steen NE, Birkeland KI, Dieset I, Reponen EJ, Laskemoen JF, et al. Adipokine levels are associated with insulin resistance in antipsychotics users independently of BMI. Psychoneuroendocrinology. 2019 May;103:87–95.](http://paperpile.com/b/3JPyg8/MuXy)

92. [Agaba DC, Migisha R, Katamba G, Ashaba S. Cardio-metabolic abnormalities among patients with severe mental illness at a Regional Referral Hospital in southwestern Uganda [Internet]. Vol. 15, PLOS ONE. 2020. p. e0235956. Available from:](http://paperpile.com/b/3JPyg8/rxm2) <http://dx.doi.org/10.1371/journal.pone.0235956>

93. [Hammoudeh S, Al Lawati H, Ghuloum S, Iram H, Yehya A, Becetti I, et al. Risk Factors of Metabolic Syndrome Among Patients Receiving Antipsychotics: A Retrospective Study. Community Ment Health J. 2020 May;56(4):760–70.](http://paperpile.com/b/3JPyg8/sLNV)

94. [Park S-C, Tripathi A, Avasthi A, Grover S, Tanra AJ, Kato TA, et al. Relationship Between Body Mass Index and Extrapyramidal Symptoms in Asian Patients with Schizophrenia: The Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP). Psychiatr Danub. 2020 Summer;32(2):176–86.](http://paperpile.com/b/3JPyg8/X609)

95. [Smith J, Griffiths LA, Band M, Horne D. Cardiometabolic Risk in First Episode Psychosis Patients. Front Endocrinol . 2020 Nov 24;11:564240.](http://paperpile.com/b/3JPyg8/6OM7)

96. [Teshome T, Kassa DH, Hirigo AT. Prevalence and Associated Factors of Metabolic Syndrome Among Patients with Severe Mental Illness at Hawassa, Southern-Ethiopia. Diabetes Metab Syndr Obes. 2020 Feb 27;13:569–79.](http://paperpile.com/b/3JPyg8/E4wL)

97. [Wang J, Zhang Y, Yang Y, Liu Z, Xia L, Li W, et al. The prevalence and independent influencing factors of obesity and underweight in patients with schizophrenia: a multicentre cross-sectional study. Eat Weight Disord. 2021 Jun;26(5):1365–74.](http://paperpile.com/b/3JPyg8/YaiQ)

98. [Zavala GA, Haidar AC, Prasad-Muliyala K, Aslam F, Huque R, Khalid H, et al. The Physical Health of People With Severe Mental Illness in South Asia: A Cross-Sectional Multi-Country Survey [Internet]. SSRN Electronic Journal. Available from:](http://paperpile.com/b/3JPyg8/GCmq) <http://dx.doi.org/10.2139/ssrn.3736709>

99. [Carpiniello B, Corda E, Maccioni R, Pinna F. Schizophrenia, obesity and pharmacotherapy-associated weight gain. Clin Ter. 2008 Sep;159(5):299–306.](http://paperpile.com/b/3JPyg8/7HSr)

100. [Cerit C, Özten E, Yildiz M. The Prevalence of Metabolic Syndrome and Related Factors in Patients With Schizophrenia. Turk Psikiyatri Derg [Internet]. 2008;19(2). Available from:](http://paperpile.com/b/3JPyg8/eMyg) <http://www.turkpsikiyatri.com/Data/UnpublishedArticles/en/metabolicSyndrome.pdf>

101. [Cerit C, Yildiz M, Candan S. The prevalence of obesity and weight gain among the patients with psychotic disorder who use antipsychotic medication, one year follow-up. KLINIK PSIKOFARMAKOLOJI BULTENI. 2006;16(4):233.](http://paperpile.com/b/3JPyg8/bkqM)

102. [Cumurcu BE, Tümüklü MN, Çelikel FÇ, Demir S, Others. Metabolic side effects of atypical antipsychotic medication in outpatients of a University Hospital Clinic [Bir Üniversite Hastânesinde psikotik bozukluk hastalarinda atipik antipsikotik kullaniminin metabolik etkileri]. 2009; Available from:](http://paperpile.com/b/3JPyg8/TZYj) <http://earsiv.gop.edu.tr/xmlui/handle/20.500.12881/8533>

103. [Foguet Boreu Q, Roura Poch P, Bullón Chia A, Mauri Martin C, Gordo Serra N, Cecília Costa R, et al. Cardiovascular risk factors, cardiovascular risk and quality of life in patients with a severe mental disorder. Aten Primaria. 2013 Mar;45(3):141–8.](http://paperpile.com/b/3JPyg8/qClK)

104. [Fridthjofsdottir HG, Geirsdottir OG, Jonsdottir H, Steingrimsdottir L, Thorsdottir I, Thorgeirsdottir H, et al. [Dietary intake of young Icelanders with psychotic disorders and weight development over an 8-12 months period]. Laeknabladid. 2017 Jun;103(6):281–6.](http://paperpile.com/b/3JPyg8/jo6Q)

105. [Inamura Y, Sagae T, Kushida O, Nakamachi K, Murayama N. Survey of obesity and underweight among inpatients with schizophrenia in psychiatric hospitals throughout Japan. Seishin Shinkeigaku Zasshi. 2013;115(1):10–21.](http://paperpile.com/b/3JPyg8/mwDm)

106. [Sánchez-Araña Moreno T, Touriño González R, Hernández Fleta JL, León Pérez P. Prevalence of the metabolic syndrome among schizophrenic patients hospitalized in the Canary Islands. Actas Esp Psiquiatr. 2007 Nov;35(6):359–67.](http://paperpile.com/b/3JPyg8/trom)

107. [Bartoli DF. Disturbi mentali gravi e Sindrome Metabolica: meta-analisi e studio trasversale comparativo. Available from:](http://paperpile.com/b/3JPyg8/EtbD) <https://boa.unimib.it/bitstream/10281/42833/1/phd_unimib_734457.pdf>

108. [Rouillon F, Van Ganse E, Vekhoff P, Arnaud R, Depret-Bixio L, Dillenschneider A. Niveau de vigilance des psychiatres pour les facteurs de risque cardiovasculaire chez les patients schizophrènes. Encephale. 2015 Feb;41(1):70–7.](http://paperpile.com/b/3JPyg8/nVsU)

109. [Sveinsson O, Thorleifsson K, Aspelund T, Kolbeinsson H. A study of risk factors for cardiovascular disease among schizophrenic patients using the rehabilitation mental health services at Kleppur. Laeknabladid. 2012 Jul;98(7-8):399–402.](http://paperpile.com/b/3JPyg8/MsUo)

110. [Tenback DE, van Kessel F, Jessurun J, Pijl YJ, Heerdink ER, van Harten PN. Risk factors for inactivity in patients in long-term care with severe mental illness. Tijdschr Psychiatr. 2013;55(2):83–91.](http://paperpile.com/b/3JPyg8/Uo3M)

111. [Vasilenko LM, Gorobets LN, Bulanov VS, Litvinov AV, Ivanova GP, Tsarenko MA, et al. [Eating disorders in psychiatric patients during treatment with second generation antipsychotics]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(7):60–7.](http://paperpile.com/b/3JPyg8/K1rD)

112. [Yang P-C, Jou J-F, Wang C-W, Chong M-Y. Body Weight Changes in Chronice Psychotic Female In-Patients. 中華民國營養學會雜誌. 1997 Nov 1;22(4):457–64.](http://paperpile.com/b/3JPyg8/emf0)

113. [Yldz B, Turan MT, Beirli A. Metabolic Syndrome in Bipolar Affective Disorder. ERCYES MEDICAL JOURNAL. 33(3):197–204.](http://paperpile.com/b/3JPyg8/PKFg)

114. [Yildiz M. Weight gain in patients with schizophrenia and schizoaffective disorder under antipsychotic treatment: A three-year naturalistic follow-up study. Yildiz M, “Weight gain in patients with schizophrenia and schizoaffective disorder under antipsychotic treatment: A three-year naturalistic follow-up study”, KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, cilt [Internet]. 2008 [cited 2021 Aug 27];18. Available from:](http://paperpile.com/b/3JPyg8/Ribf) <https://avesis.kocaeli.edu.tr/yayin/f3582b6f-814c-4d5d-a178-f9fcb9d25573/weight-gain-in-patients-with-schizophrenia-and-schizoaffective-disorder-under-antipsychotic-treatment-a-three-year-naturalistic-follow-up-study>